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General introduction 
8 | Chapter 1
General aspects of subarachnoid haemorrhage
Epidemiology 
Subarachnoid haemorrhage (SAH) is bleeding into the subarachnoid space ‒ the 
area between the arachnoid membrane and the pia mater surrounding the brain. 
SAH occurs spontaneously or can be caused by traumatic injury of the head. 
Spontaneous SAH is caused by rupture of an intracranial aneurysm in 85 percent 
of cases [1]. In this thesis we consider both spontaneous SAH in general and in 
several studies aneurysmal SAH specifi cally. 
 Reliable knowledge about the risks of (aneurysmal) SAH in diff erent 
populations will help in planning, screening and prevention strategies and in 
predicting the prognosis of individual patients. The overall incidence of SAH is in 
general between 5 and 10 per 100,000 person years. However, in Japan and Finland 
rates are as high as 20 per 100,000 person years [2]. This can partly be explained 
by genetic and environmental diff erences between these and other countries [3, 4]. 
The incidence increases with age; and from midlife onwards incidence is higher 
in women than in men [2]. The reasons for this higher incidence in women are not 
clear, but hormonal factors (including hormonal medication) have been suggested 
as a possible explanation [5,6]. 
Diagnosis and Treatment 
Sudden headache is the most characteristic symptom of SAH; in approximately 
75 percent of patients, the onset is within seconds [7]. Oft en, the headache is 
accompanied by nausea and vomiting. Headache from SAH is diff use and 
described by patients as by far the most severe headache they have ever had. It is, 
however, not the severity, but the suddenness of onset, which is the characteristic 
feature ‒ but a feature that patients oft en forget to mention because it is the 
severity of the pain for which they seek medical att ention [1]. On admission two-
thirds of all patients have depressed consciousness, of whom half are in coma [8]. 
The patient might regain alertness and orientation or might remain with various 
degrees of lethargy, confusion, or agitation. An acute confusional state can occur 
and be misinterpreted as psychological in origin [9, 10]. Neck stiff ness is a common 
symptom, caused by the infl ammatory response to blood in the subarachnoid 
space. Neck stiff ness takes a couple of hours to appear and might not develop at 
all in deeply unconscious patients, or in patients with minor SAH [11]. Therefore, 
absence of neck stiff ness can never exclude the diagnosis of SAH in a patient with 
sudden headache [1]. 
 The fi rst investigation when SAH is suspected is computed tomography (CT) 
to visualize the SAH. A second step is to examine the presence and localisation of 
intracranial aneurysms. This can be done by either digital subtraction angiography 
(DSA) or CT-angiography (CTA). Unruptured intracranial aneurysms (UIA) are 
present in approximately 2 percent of the general population [12, 13]. The risk of 
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rupture of an UIA, leading to an aneurysmal SAH is around 2 percent per year 
[12]. In case of an aneurysm as cause of the SAH, the aneurysm must be treated 
to prevent rebleeding. The aim of treatment is to exclude the aneurysm from the 
blood circulation. That aim can be achieved by placing a clip over the neck of an 
aneurysm during a neurosurgical procedure, or by fi lling the aneurysm with a coil 
during an endovascular procedure [14-16]. Other less frequently used treatment 
modalities comprise wrapping, stenting, or balloon occlusion [17-19]. Causes of 
spontaneous SAH from other origins include other vascular lesions, infl ammatory 
and non-infl ammatory lesions, tumours, and drug or substance use [1, 20]. Patients 
in whom no cause is found do not undergo any treatment and usually have an 
excellent prognosis [21].
Aetiology
Systematic reviews have been performed to present current knowledge on risk 
factors for SAH in a systematic way [22]. Established modifi able risk factors for 
SAH are hypertension, smoking, and excessive alcohol intake, all of which more-
or-less double the risk [23]. However, their roles in underlying mechanisms of SAH 
occurrence are poorly understood and are essentially limited to their statistical 
associations [24]. Another group of modifi able risk factors consists of medication. 
A wide range of chemical substances has been examined with regard to risk of 
stroke or SAH [6, 23, 25-28]. However, in several studies it remained unclear 
whether and to what extent the drugs under study were associated specifi cally 
with SAH, as this was not separated out [25, 29]. Other studies led to contradicting 
results [23, 26]. To address some of the uncertainties from previous studies, we 
examined in this thesis the association between SAH and three drug classes; 
statins, antithrombotics, and oral contraceptive pills (OCP). 
 Statins aff ect the endothelium through increased nitric oxide (NO) 
bioavailability [30]. Withdrawal of statins causes a rebound eff ect leading to 
increases in vascular event rates beyond that of the absence of prevention alone [27]. 
This observed rebound eff ect has been att ributed to the inhibition of endothelium 
NO synthase (eNOS) mediated pathways by statins [27]. Withdrawal of statins 
is supposed to impair the eNOS mediated tension regulation, which in turn may 
lead to short term increased stress on the vessel wall and risk of SAH. 
 Use of antithrombotic agents has been associated with increased risk of 
intracranial haemorrhage (ICH) [28]. It remains unclear whether and to what 
extent these antithrombotic agents are associated specifi cally with SAH, as this is 
regularly not separated out [25, 29]. 
 Since incidence patt erns of SAH diff er between men and women in diff erent 
age categories, hormonal infl uences have been suggested [2]. Others concluded 
that OCP use promotes endothelial dysfunction [31]. 
 Genetic factors account for approximately 10 percent of spontaneous SAH 
[32]. Most research in the genetic fi eld has focussed on genetics of intracranial 
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aneurysms. Candidate genes for intracranial aneurysms identifi ed thus far include 
genes coding for elements of the extracellular matrix [33], endothelial cells [34], 
and cell cycle progression [35]. The exact mechanisms leading to rupture of an 
intracranial aneurysm remain to be clarifi ed. A plausible explanation is a peak in 
the arterial blood pressure [1]. Such a peak can be caused by heavy physical exercise 
(including sexual intercourse) or substance use, e.g. cocaine [36-38]. However, in 
the majority of SAH cases the exact reason for occurrence at a particular point in 
time remains unexplained [1]. 
Outcome
Case-fatality aft er SAH has been estimated between 20 and 50 percent [39, 40]. 
The percentage of persons dying before they reach a hospital has been estimated 
between 10 and 15 percent [41, 42]. In those who survive the fi rst episode of SAH, 
epilepsy develops aft er discharge in approximately fi ve percent of patients [43, 
44]. Cognitive defi cits and psychosocial dysfunction in the fi rst year aft er SAH 
are common, even in patients who make a good recovery in terms of self care [45-
47]. Although improvement can be expected up to one and a half year aft er SAH, 
many former patients experience defi cits and reduced quality of life 1 to 2 years 
aft er SAH [48].
Aims and outline of this thesis
The work in this thesis was conducted as part of the @neurIST project, a European 
Commission funded project focusing on integration of knowledge on intracranial 
aneurysms from molecular level up to population level. One of the overall aims 
of the project was to develop an individualised prediction model that would 
allow predicting behaviour of an unruptured aneurysm and outcome of eventual 
rupture of an aneurysm. To reach this fi nal aim, several intermediate questions 
have to be solved. In this thesis we address several of these.
The aim of this thesis is to provide answers to the following questions:
1. What is the incidence and case-fatality of (aneurysmal) SAH in the general 
population?
2. Can we estimate the association between prescribed drugs and the risk of 
(aneurysmal) SAH?
3. Can we identify new genetic risk loci for intracranial aneurysms?
4. Which patient and aneurysm characteristics predict outcome aft er aneurysmal 
SAH?
This introductory chapter gave a high level overview of already available 
knowledge. We consider it to be desirable to obtain further knowledge on several 
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aspects of (aneurysmal) SAH. Although much has been writt en on clipping and 
coiling of intracranial aneurysms, it remains to be established how these treatment 
modalities are applied in real life clinical sett ings, and what the outcome is. In 
the fi eld of aetiology, systematic research in the association between drugs and 
(aneurysmal) SAH lacks. The role of genetics also needs to be elucidated more. To 
fi nally reach the aim of individualized prediction models, eff ort has to be put in 
development of prediction models for various outcomes in diff erent stages of the 
disease. 
 In chapter 2 the occurrence of (aneurysmal) SAH in the general population 
is examined as well as case-fatality and treatment modalities that were applied. 
The incidence rate tells us how many SAHs occur per 100,000 persons per year. 
Why these SAHs occur remains to be established, since the exact mechanisms 
underlying SAH remain incompletely understood. However, there are indications 
that external factors -amongst which drug use- play a role in the aetiology of SAH. 
 Therefore, in chapter 3 we investigated several risk factors for (aneurysmal) 
SAH. The most important were drugs whose mode of action was thought to 
interact with the physiology of blood vessels -more specifi c: arteries- and therefore 
may play a role in the aetiology of SAH. Statins are protective for cerebrovascular 
events and withdrawal of statins causes a rebound eff ect leading to increases in 
vascular event rates beyond that of the absence of prevention alone [27]. This 
observed rebound eff ect has been att ributed to the inhibition of endothelium NOS 
(eNOS) mediated pathways by statins [27]. Withdrawal of statins is supposed 
to impair the eNOS mediated tension regulation, which in turn may lead to 
short term increased stress on the vessel wall and risk of SAH. To investigate 
this potential mechanism we studied the association of statin withdrawal and 
SAH in chapter 3.1. Antithrombotic agents have been associated with increased 
risk of intracranial haemorrhage [28, 49]. Since their role in precipitating SAH 
remains to be elucidated, we studied the relation between SAH risk and the use 
of antithrombotic agents in chapter 3.2. A specifi c subgroup of the population was 
under study in chapter 3.3; since quite some time use of oral contraceptive pills 
(OCP) has been associated with vascular pathology, amongst which stroke. Also, 
hormonal factors have been suggested to explain sex diff erences in SAH incidence 
[5, 6]. To investigate whether there was an eff ect on SAH risk in OCP users, we 
studied the association in a population of women under 50 years of age. Chapter 
3.4 describes the work of a consortium on genetic factors that are associated with 
aneurysmal SAH. Genetic factors were investigated by pooling genetic data from 
patients in several populations including data collected by us from IPCI and 
Erasmus MC cases and controls. 
 In chapter 4 we were interested in factors that actually predict outcome of 
aneurysmal SAH. Prediction of outcome may support clinical decision making 
and may provide realistic and evidence based expectations to patients and 
relatives. Predictions may also be used to classify patients according to prognostic 
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risk, which may be useful to compare outcome between diff erent patient series, 
to study treatment results over time, or to stratify patients for randomised clinical 
trials. We developed a prediction model for outcome of aneurysmal SAH based on 
clinical information that is already available in an early stage of hospital admission. 
The prediction model was based on a re-analysis of data from the ISAT study, 
one of the larger clinical trials in the fi elds of aneurysmal SAH. In chapter 4.1 we 
present a prediction model for 60 day case-fatality in patients with an aneurysmal 
SAH who were in equipoise with regard to best treatment option. As potential 
predictors we investigated clinical and neuroradiological characteristics of patient 
and aneurysm. Aft er model selection and internal validation, we developed a 
prediction model based on two clinical and two neuroradiological characteristics. 
To extend the usability of our model we expanded the outcome from 60 day case-
fatality to outcome on an ordered clinical outcome scale; the modifi ed Rankin 
scale. Results of this model development exercise are presented in chapter 4.2. 
 The signifi cance and methodological issues of the studies presented in this 
thesis will be discussed in chapter 5. Findings from this thesis will we summarized 
in chapter 6.
Chapter 2 
Incidence, treatment, and case-fatality of subarachnoid 
haemorrhage in the Netherlands 
14 | Chapter 2
Abstract
Background: Subarachnoid haemorrhage (SAH) is a devastating disorder and in 
the majority of cases caused by rupture of an intracranial aneurysm. No actual 
data are available on the incidence of SAH and aneursymal SAH (aSAH) in the 
Netherlands and litt le is known about treatment patt erns of aSAH. Our purpose 
was therefore to assess the incidence, treatment patt erns, and case-fatality of (a)
SAH within the Dutch general population. 
Methods: Two population based data sources were used for this retrospective 
cohort study. One was the nationwide hospital discharge registry (LMR). Cases 
were patients hospitalized for SAH (ICD-9-code 430) in 2001-2005. The second 
source was IPCI, a medical record database allowing for case validation. Cases 
were patients with validated (a)SAH in 1996-2006. Incidence, treatment, and case-
fatality were assessed.
Results: The incidence rate (IR) of SAH was 7.12 per 100,000 PY (95%CI: 6.94-7.31) 
and increased with age. The IR of aSAH was 3.78 (95%CI: 2.98–4.72). Women had 
a twofold increased risk of SAH; this diff erence appeared aft er the fourth decade. 
SAH fatality was 30% (95%CI: 29-31%). Of aSAH patients 64% (95%CI: 53-74%) 
were treated with a clipping procedure, and 26% (95%CI: 17-37%) with coiling.
Conclusion: SAH is a rare disease with substantial case-fatality; rates in the 
Netherlands are similar to other countries. Case-fatality is also similar as well as 
age and sex patt erns in incidence.
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Introduction
Non-traumatic subarachnoid haemorrhage (SAH) is a devastating event, with 
a case-fatality of around 30 percent [1, 40]. Incidence rates have been assessed 
in many countries and two patt erns can be distinguished: countries with high 
incidence of around 20 per 100,000 person years (PY), such as Finland and Japan, 
and countries with low incidence of approximately 5-10 per 100,000 PY [2].
 Approximately 85 percent of SAH is a result of rupture of an intracranial 
aneurysm (IA), although it is not clear whether this percentage is the same over 
diff erent age and sex categories [1]. Causes of spontaneous SAH from other origins 
include other vascular lesions, infl ammatory and non-infl ammatory lesions, 
tumours, and drug or substance use [1, 20]. 
 The diagnosis of SAH is primarily based on CT imaging and lumbar puncture, 
eventually followed by angiography; not only to identify an aneurysm as potential 
cause of the haemorrhage, but also to study the anatomical and morphological 
confi guration of the aneurysm in relation to adjoining arteries, which allows 
optimal treatment selection [1]. Treatment of aneurysmal SAH (aSAH) consists 
mainly of either neurosurgical clipping or endovascular coiling. Other less 
frequently used treatment modalities comprise wrapping, stenting, or balloon 
occlusion [17-19].
 Given the fact that no recent data on age and sex specifi c incidence of SAH 
and aSAH in the Netherlands are available, we assessed the incidence of both 
conditions in the general Dutch population. Moreover, we studied case-fatality, 
and treatment modalities applied to aSAH patients. This was done in two 
population based databases; a national discharge database and a smaller medical 
record database which allowed for assessment of the presence of an aneurysm and 
treatment modality.
 
Materials and methods
LMR database
Hospital discharge diagnoses were obtained from the national registry of hospital 
admissions, the National Medical Registration (LMR), containing information on 
all admissions in general and academic hospitals throughout the Netherlands (base 
population: approximately 16.5 million subjects). The International Classifi cation 
of Diseases, Ninth Revision, Clinical Modifi cation (ICD-9-CM) was used to classify 
hospital admissions in the Netherlands during the study period. Data used include 
hospital code, patient sex and age, ICD-9-CM coded discharge diagnosis, up to 9 
diagnostic or therapeutic procedures (coded according to the LMR Classifi cation 
of Diagnostic, Therapeutic, and Surgical Acts), and discharge destination (‘home’, 
‘old people’s home’, ‘nursing home’, or ‘died in hospital’).
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SAH cases were all admissions with a primary discharge diagnoses (ICD-9-CM) 
430 (subarachnoid haemorrhage) during the years 2001 through 2005. Case-fatality 
was defi ned as dying in the hospital during hospitalization for SAH.
 The denominator for the incidence calculation was the annual mid-year 
population size as obtained from Statistics Netherlands (CBS, accessed through 
htt p://www.cbs.nl, as of June 7th, 2010).
IPCI database
The Integrated Primary Care Information (IPCI) database is a general practice 
research database with electronic medical record data currently comprising more 
than one million patients throughout the Netherlands. The patient population 
is representative of the Dutch population regarding age and sex [50]. Details of 
the database have been described elsewhere [51]. The system complies with the 
European Union guidelines on the use of medical data for research and has been 
proven valid for epidemiological studies [51]. The Scientifi c and Ethical Advisory 
Group of the IPCI project approved the study (Project No. 07/02). The database 
allows for validation of disease by requesting additional information from the 
general practitioner by questionnaire and copies of original specialist lett ers.
 Potential cases of SAH and aSAH were identifi ed from the IPCI database 
using an extensive narrative search. All cases were validated by manual review of 
the electronic medical record and subsequently by review of a questionnaire and 
specialist lett ers that were obtained from the GP for each case. The validity of the 
diagnosis was judged by a medical doctor (R.R.) and a neurologist (D.W.J.D. or 
F.K.). The judgment of the neurologist was decisive. Case-fatality was defi ned as 
dying within a period of 30 days aft er the date of onset of SAH (index date).
 The denominator for the incidence calculation was the number of person 
years in the IPCI database during the study period (January 1996–September 
2006).
Statistical analysis
The incidence rate of SAH and aSAH was calculated by dividing the number of 
incident cases (numerator), by the total number of accrued person years (IPCI) 
or persons (LMR) in the study population (denominator). Incidence rates (IR) 
were calculated in age and sex categories. Confi dence intervals (95% CI) for each 
estimate were based on the Poisson distribution. To estimate case-fatality of aSAH 
in the IPCI database, Kaplan-Meier survival analysis was used. Incidence rates 
were used to calculate rate ratios of SAH and aSAH between females and males. 
All analyses were performed using SPSS soft ware version 15.0 (Chicago, Ill., USA).
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Results 
LMR: SAH
In the period 2001 to 2005 a total of 5,769 patients (64% female) were admitt ed 
to Dutch hospitals with discharge diagnosis ‘subarachnoid haemorrhage’. The 
overall nationwide incidence rate of SAH was 7.12 per 100,000 person-year (PY) 
(95% CI: 6.94-7.31) (Table 1). The incidence rate rapidly increased with age (Table 
1, Figure 1). The overall incidence rate ratio (IRR) of SAH for women compared to 
men was 1.72 (95% CI: 1.63-1.81). This diff erential risk occurred gradually and was 
most pronounced in the fourth and fi ft h decade (Table 1, Figures 1). Case-fatality 
for SAH during hospitalization was 30 percent (95% CI: 29-31%), and increased 
with age, but did not diff er between males and females (Table 1).
Figure 1. Sex Specifi c Incidence Rates of SAH in 5 year age bands in LRM data. Solid lines 
are estimated rates, dashed lines the 95% confi dence bands; grey line for women, black 
line for men.
IPCI database: SAH and aSAH
In the initial source population of 488,118 persons, 107 incident cases of SAH (70% 
female) were identifi ed aft er validation (Table 1). Based on these data the observed 
crude rate was 5.53 per 100,000 PY (95% CI: 4.56-6.66) (Table 1), which translates to 
a rate of 6.48 per 100,000 PY in the Netherlands aft er standardization to the Dutch 
age and sex distribution. The incidence rate increased with age and was similar to 
the LMR rates up until 64 years; rates were lower aft er that (Table 1). 
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In 68 percent of all IPCI derived SAH cases (n=73) an aneurysm had been diagnosed 
(95% CI: 59-76%). The proportion of aneurysms as cause of SAH diminished with 
age (Figure 2). 
 The crude observed incidence rate of aSAH was 3.78 per 100,000 PY (95% CI: 
2.98-4.72), which would imply a rate of 4.26 per 100,000 for the Dutch population 
(age and sex standardized). Of the patients with an aneurysm the majority was 
treated by means of a neurosurgical clipping procedure (64%, 95% CI: 53-74%) 
and 26 percent (95% CI: 17-37%) by means of endovascular coiling. Five patients 
(7%) did not receive any treatment because of rapid deterioration and death. In the 
remaining 3 percent we could not fi nd information on procedures. 
 Kaplan-Meier survival analysis showed that 26 percent of SAH patients died 
within 30 days (95% CI: 17-34%) (Table 1). Case-fatality in aSAH patients was 
5.6 percent (95% CI: 0.31-10.9) (Table 1). Risks could not be estimated in separate 
treatment groups due to low numbers.
Figure 2. SAH and aSAH incidence rate by age (IPCI database) 
Discussion 
We used two diff erent population based databases: a hospital discharge database 
and an electronic medical record database to assess the occurrence, treatment, 
and case-fatality of SAH and aSAH in the Netherlands. We used both sources 
to profi t from the size in the LMR and the quality of information and validation 
opportunities in the IPCI database. By using these data we revealed various 
important observations: fi rst, the crude national incidence rate of SAH was 
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between 5-7 cases per 100,000 PY, putt ing the Netherlands in the low incidence 
countries. Second, about 70 percent of SAHs were of proven aneurysmal origin 
and this varied slightly by age (lower in high ages). Third, case-fatality of SAH was 
high: around 26 percent within one month and this increased with age. Fourth, a 
striking age and gender patt ern was observed in the incidence rates. The incidence 
rates increased rapidly aft er age 40, but mostly so for women. Fift h, the incidence 
rates for aSAH increased less rapidly with age than for SAH overall, suggesting 
a diff erence in the percentage of aneurysms by age. Sixth, the majority of persons 
with an aSAH underwent surgical clipping. 
 Our fi ndings on the rates and case-fatality were similar to previously published 
population-based studies from other countries. However, oft en the rates for aSAH 
are not available. The assumption that 85 percent of SAH is based on aneurysms, 
may therefore not hold true and certainly not for all age categories. Some of the 
previous studies have investigated sex specifi c rates and age-gender interaction, 
and also reported higher rates in women; however the age dependent change in 
incidence for women compared to men was reported few times. The reasons for 
the overall higher incidence in women are not clear, but hormonal factors would be 
a fi rst logical option [5, 6]. Our fi nding that the preponderance of women becomes 
evident around the menopause, during which changes in oestrogen levels take 
place, further supports this suggestion. Previously, an increase in cardiovascular 
risk among women aft er menopause has been recognized [52], for which declining 
endogenous oestrogen levels have been held responsible [53]. Declining levels 
of oestrogen might lead to impaired activation of nitric oxide [54], which is 
hypothesized to be an important factor in the aetiology of SAH through its eff ects 
on the vascular endothelium [55, 56]. 
 Being based on observational data the results of our study should be interpreted 
in the light of potential limitations, such as selection bias and information bias. 
Selection bias in assessment of rates and case-fatality is negligible in this study 
since we used population based databases. Selection may have occurred because 
validation of the discharge diagnoses for the LMR was done only in our hospital. 
Results of this validation may not be generalizable to all other centres. Thus, the 
most important limitation is misclassifi cation of the outcome. For a patient to be 
considered a case in our study, the diagnosis SAH had to be made. Patients who 
died before reaching medical care were not included in the LMR estimate and it 
is highly likely that they were also missed in the IPCI database due to lack of a 
proper diagnosis and specialist information. Previous studies have estimated the 
percentage of persons dying outside hospitals to be between 11 and 13 percent [41, 
42]. This means that the true incidence is potentially 10 percent higher than in our 
estimations (up to 8 per 100,000 PY). Another potential limitation is the accuracy 
of the registered diagnosis in the LMR database. Validation of discharge diagnoses 
in our own hospital showed that 10 percent of the cases were false positive (data 
not shown). Inclusion of these false positive cases in incidence estimates would 
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lead to overestimation. In the IPCI database, false positives were unlikely, since 
cases were validated. In both databases false negative misclassifi cation has not 
been quantifi ed. We think it is limited in the IPCI database as we applied a very 
sensitive search on codes and free text to identify potential cases and reviewed all 
potential cases manually. 
 Misclassifi cation of mortality was an issue in the LMR database. Since 
the database only captures data during hospitalizations and is not linked to 
a death registry, it is not possible to obtain mortality data of patients once they 
are discharged from the hospital. We therefore chose to report on the mortality 
during hospital admission only. Nonetheless, the case-fatality is comparable to 
the case-fatality as estimated from the IPCI database that does capture follow-up 
and mortality data. This implies that most cases die oft en immediately and mostly 
during hospitalization. Case-fatality of aSAH patients is remarkably low and may 
not represent true fatality of an aneurysmal SAH (Table 1). Severe cases may have 
died before undergoing imaging; in that case an aneurysm could not be proven. 
Less severe cases will probably have survived the 30 day period.
 The strength of this study is that two separate databases were used to address 
not only SAH but also aSAH. Both are observational and our study showed that 
they can be used complementary. Discharge databases are large which allows for 
fi ne stratifi cation, but medical record databases allow for depth and more clinical 
insight. Together they have provided thorough insight in the occurrence, case-
fatality, and treatment of (a)SAH.
 In conclusion, in this study we showed SAH incidence in the Netherlands is 
in the range of the low-incidence countries. We demonstrated that the incidence 
for both SAH and the subgroup of aSAH depends highly on age and sex but the 
patt erns for aSAH might be slightly diff erent than for SAH overall.
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3.1 Withdrawal of statins and risk of subarachnoid haemorrhage
Background and purpose: Vascular endothelium, which can be aff ected by statins, 
is believed to play a substantial role in subarachnoid haemorrhage (SAH). Our 
objective was to estimate the association between use and withdrawal of statins 
and the risk of SAH.
Methods: We conducted a population-based case-control study within the 
PHARMO database. A case was defi ned as a person hospitalised for SAH (ICD-9-
CM code ‘430’) in the period 01.01.98-12.31.06. Ten randomly chosen controls were 
matched to each case on age, gender, and calendar date.
Results: During the study period 1004 incident cases of SAH were identifi ed. 
Current use of statins did not signifi cantly decrease the risk of SAH (OR=0.77, 
95%CI 0.55-1.07). The odds ratio for recent withdrawal compared to none users 
was 1.62 (95%CI 0.96-2.73). Compared to current use, recent withdrawal was 
associated with an increased risk of SAH (OR=2.34, 95%CI 1.35-4.05). Interaction 
analysis showed that the eff ect of statin withdrawal was highest in patients who 
had also recently stopped anti-hypertensive drugs (OR=6.77, 95%CI 2.10-21.8). 
Conclusions: Current use of statins seems to lower the risk of SAH, although the 
reduction was not signifi cant in new users. Statin withdrawal increased the risk of 
SAH by a factor 2, even more in patients who had also recently stopped their anti-
hypertensive treatment. 
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Introduction 
Subarachnoid haemorrhage (SAH) is a severe neurological disorder [1]. Modifi able 
risk factors for SAH are hypertension, smoking, and excessive alcohol intake [1]. 
Drugs may comprise another class of risk factors, but their role in SAH aetiology 
has not been systematically evaluated. Considering the potential role of vascular 
endothelium in SAH [55], drugs aff ecting the endothelium might be expected 
to alter SAH risk. Statins aff ect the endothelium through increased nitric oxide 
bioavailability and have been shown to ameliorate SAH-induced vasospasm [30, 
69]. Although statins decrease cerebrovascular event rates during use, withdrawal of 
statins causes a rebound eff ect leading to increases in vascular event rates beyond 
that of the absence of prevention alone [27]. This observed rebound eff ect has 
been att ributed to the inhibition of endothelium NOS (eNOS) mediated pathways 
by statins [27]. Withdrawal of statins is supposed to impair the eNOS mediated 
tension regulation, which in turn may lead to short term increased stress on the 
vessel wall and risk of SAH.
 We hypothesized that statins infl uence the risk of SAH during use (decrease) 
and shortly aft er withdrawal (increase). To examine these hypotheses we conducted 
a population-based case-control study in the general Dutch population. 
Patients and methods
Sett ing
Data were obtained from PHARMO Record Linkage System (RLS), a population 
based system with dispensing data and hospitalizations regarding a well-
enumerated population and follow-up. For a detailed description of the database 
we refer to previous work [70].
 The source population included all persons in the PHARMO RLS database 
who had at least three years of valid database history prior to the index date (see 
below). Persons were followed from inception or start of the study period (January 
1st, 1998) until transferral out of the database, death, diagnosis of SAH, or the end 
of the study period (December 31st, 2006). 
Cases and controls
Study outcome was hospitalisation for a fi rst SAH, as recorded in the Dutch 
National Medical Registration (LMR) with ICD-9-CM code ‘430’. To assess the 
positive predictive value (PPV) of the LMR information discharge lett ers of 42 
patients were evaluated. 
 For each case 10 controls were obtained from the source population and 
matched to the case on year of birth, gender, and index date (ID). 
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Drug exposure and covariates
The drugs of primary interest were statins. Use was classifi ed as ‘no’, ‘current’ (use 
at ID), ‘recent withdrawal’ (stopping up to 30 days before ID), and ‘past’ (stopping 
> 30 days before ID). To inspect protopathic bias we looked at ‘recent starters’ 
(current use less than 30 days), to limit prevalent user bias (healthy users) current 
use was restricted to short term use (< 3 years). 
 We considered diabetes mellitus (DM), a history of vascular events, and 
hypertension as covariates. Use of insulin without a history of use of oral anti-
diabetic agents was considered a proxy for having DM type I. Use of oral anti-
diabetic agents either or not followed by use of insulin was considered a proxy for 
having DM type II. A history of vascular events was defi ned by use of two or more 
prescriptions of nitrates, or of either aspirin or clopidogrel or hospitalisation for 
ischemic cardio- or cerebrovascular events (CVD). Past use of antihypertensives 
was considered a proxy for uncontrolled hypertension. 
 All drugs with potential eff ect on the eNOS pathway were considered as 
co-variates (table 1). We also studied agents known for increased bleeding risk, 
as well as NSAIDs, coxibs, tricyclic antidepressants (TCA), benzodiazepines, 
antipsychotics, anti-epileptic drugs, female sex hormones, and antibiotics.
Statistical analysis
Conditional logistic regression analysis was used for matched case-control data to 
estimate odds ratios (OR) and 95% confi dence intervals (CI) for SAH associated 
with exposure to drugs. Analyses were performed with reference to ‘no use’, and 
subsequently to ‘current use’ to bett er adjust for confounding by indication. In the 
adjusted model we included all factors that changed the eff ect estimate with more 
than 5%. 
 Sensitivity analyses were conducted on time intervals for recent withdrawal, 
information bias due to hospitalization (patients hospitalized in days before) and 
new users to avoid a healthy user bias. Eff ect modifi cation was investigated for 
gender, a history of ischemic CVD, and use of antihypertensives. 
 Association measures for products with exposure in less than 3 cases or 3 
controls are not reported. 
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Table 1. Characteristics of the study population.
 Cases Controls OR 95% CI
No % No %
Total 1004 100 10033 100
Mean age (SD) (years)  58 (14) 58 (14) Matched
<50 years 293 2928
50-65 years 383 3828
>65 years 328 3277
Gender, female 670 67 6695 67 Matched
Diabetes mellitus I  12  1.2   84  0.8 1.42 0.77-2.62
Diabetes mellitus II  57  5.7  649  6.5 0.87 0.66-1.16
History of CV events 152 15.1 1254 12.5 1.30 1.07-1.59
Anti-hypertensive drug use1
Current use 254 25.3 2560 25.5 1.05 0.89-1.25
Recent withdrawal  20  2  231  2.3 0.91 0.57-1.46
Past use 152 15.1 1197 11.9 1.34 1.10-1.62
Current use of medication with increased bleeding risk2
Vitamin K antagonists  39  3.9  283  2.8 1.43 1.01-2.03
Platelet aggregation inhibitors 111 11 1032 10 1.18 0.94-1.48
Heparin  13  1.3   96  1 1.35 0.75-2.41
SSRIs  32  3.2  335  3.3 0.96 0.67-1.40
NSAID  80  8  357  3.6 2.34 1.77-3.09
Use for > 30 days  37  3.7  297  3 1.3 0.90-1.87
COX-2 selective inhibitors  13  1.3   56  0.6 2.35 1.27-4.36
Use for > 30 days   7  0.7   43  0.4 1.65 0.74-3.70
Current use of other drugs
TCAs  10  1  117  1.2 0.85 0.44-1.64
Benzodiazepines (BZD) 102 10.2  764  7.6 1.43 1.13-1.80
 BZD > 30 days  74  7.4  740  7.4 1.04 0.80-1.36
Antipsychotics  10  1  119  1.2 0.83 0.44-1.59
Anti-epileptics  15  1.5  121  1.2 1.26 0.73-2.17
Estrogens  15  1.5  142  1.4 1.05 0.61-1.80
Progesterone   3  0.3   68  0.7 0.42 0.13-1.35
Combinations of estrogens and 
progestins  77  7.7  676  6.7 1.29 0.96-1.74
Antibiotics  19  1.9  145  1.4 1.36 0.83-2.23
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 Cases Controls OR 95% CI
No % No %
Total 1004 100 10033 100
Use of medication aff ecting endothelium
Anti-migraine
Current use   6  0.6   23  0.2 2.69 1.09-6.60
Use > 30 days   2  0.2   20  0.2 - -
Recent withdrawal   7  0.7   46  0.5 1.58 0.71-3.53
Past use  59  5.9  406  4.0 1.50 1.13-1.98
No use 932 92.8 9558 95.3 Ref.
Systemic Corticosteroids
Current use  14  1.4  112  1.1 1.24 0.70-2.17
Recent withdrawal   3  0.3   79  0.8 0.38 0.12-1.19
Past use 182 18.1 1872 18.7 0.96 0.81-1.14
No use 805 80.2 7970 79.4 Ref.
Nitrates2
Current use 28 2.8 264  2.6 1.10 0.74-1.66
Recent withdrawal 3 0.3 41  0.4 0.75 0.23-2.44
Past use 85 8.5 707  7.0 1.24 0.97-1.59
No use 888 88.4 9021 89.9 Ref.
β-blockers
Current use 117 11.7 1280 12.8 0.93 0.75-1.14
Recent withdrawal 12 1.2 139  1.4 0.88 0.48-1.59
Past use 135 13.4 1114 11.1 1.23 1.01-1.50
No use 740 73.7 7500 74.8 Ref.
Calcium channel blockers
Current use 56 5.6 569  5.7 1.02 0.76-1.36
Recent withdrawal 6 0.6 60  0.6 1.03 0.44-2.40
Past use 74 7.4 563  5.6 1.35 1.05-1.75
No use 868 86.5 8841 88.1 Ref.
RAS drugs
Current use 126 12.5 1168 11.6 1.14 0.93-1.40
Recent withdrawal 10 1 123  1.2 0.86 0.45-1.65
Past use 66 6.6 422  4.2 1.65 1.25-2.17
No use 802 79.9 8320 82.9 Ref.
1 compared to no use
2 current use compared to no use
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Results
Our study population comprised 1004 cases of SAH and 10,033 matched controls. 
The PPV of the discharge diagnosis was 88% (95%CI 75%-95%). The PPV did not 
diff er signifi cantly (p=0.26) between statin exposed and unexposed cases. 
 Past use of antihypertensives was associated with an increased risk of SAH 
(table 1). NSAIDs, coxibs, and benzodiazepines increased the risk; however, 
exclusion of recent starters weakened the eff ect, which points to protopathic bias. 
Current use of statins was associated with a reduction in SAH risk, but this eff ect 
was not statistically signifi cant when restricting to new users (table 2). Exclusion 
of patients hospitalized in the 30 days prior further att enuated the eff ect (OR=0.79, 
95%CI .56-1.12).
 Compared to no use recent withdrawal of statins was associated with a 
non-signifi cant increased risk of SAH (table 2). Recent withdrawal of statins was 
associated with a 2-fold increase in risk when compared to current users of statins: 
ORadjusted =2.34 (95%CI 1.35-4.05) (table 2), this remained when current users 
were restricted to new users (OR=2.23, 95% CI 1.24-4.02) (not shown). The eff ect 
of withdrawal was most outspoken aft er withdrawal of atorvastatin. Sensitivity 
analyses on diff erent risk windows of withdrawal showed that the association 
measure is highest when withdrawal is closest to the index date, i.e. persons who 
stopped more recently. 
 Stratifi cation by gender did not reveal signifi cant diff erences, although women 
seem to be more susceptible to statin withdrawal (table 3). A history of CVD did 
not modify the association, although the eff ects of current use and withdrawal 
were stronger in patients with CVD (table 3). Use of antihypertensives modifi ed 
the eff ect of statins; in persons who stopped statins and antihypertensives the risk 
of SAH was more than six-fold increased compared to current users of both statins 
and antihypertensives (table 3). 
Discussion
In this study we showed that statins are associated with the risk of SAH. Whereas 
current use of statins may protect against SAH, withdrawal is associated with a 
clear increase in risk, especially if patients have also stopped antihypertensive 
drugs. The observed results support our hypothesis that statins have an eff ect on 
vascular endothelium. An important fi nding is the interaction between stopping 
of statins and having stopped use of antihypertensives, especially since statins 
and antihypertensives are oft en prescribed concomitantly and non-adherence 
frequently aff ects both types of drugs [71]. The apparent protective eff ect during 
current use of statins requires confi rmation in additional studies with richer clinical 
details as the results were susceptible to analyses aiming to evaluate healthy user 
bias. 
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Results of this study should be seen in the light of limitations inherent to 
observational studies with non-random treatment-assignment. Information 
bias may occur on the level of outcome or exposure. Despite errors in exposure 
assessment due to non-compliance, information bias is likely to be non-diff erential 
since data were gathered prospectively without knowledge of the hypothesis 
studied and withdrawal eff ects were not observed for other non-CNS and 
non-endothelium aff ecting drugs [72, 73]. Misclassifi cation of exposure due to 
hospitalization prior to the index date was ignorable.
Table 2. Statin use and the association with SAH. 
Cases 
N
% Controls 
N
% ORunadjusted 95% CI ORadjusted  95% CI
Statin use with reference to no use
Current use† 82 8.2 976 9.7 0.84 0.66-1.07 0.71 0.54-0.93
Simvastatin 38 3.8 412 4.1 0.92 0.65-1.29 0.79 0.55-1.13
Pravastatin 12 1.2 182 1.8 0.66 0.36-1.19 0.53 0.29-0.97
Fluvastatin 2 0.2 34 0.3 ‒
Atorvastatin 25 2.5 287 2.9 0.87 0.57-1.32 0.73 0.47-1.13
Cerivastatin 0 0.0 4 0.0 ‒
Rosuvastatin 5 0.5 57 0.6 0.87 0.35-2.20 0.76 0.30-1.92
 New users only 
 (< 3 years)$ 46 4.6 503 5.0 0.91 0.66-1.24 0.77 0.55-1.07
Recent withdrawal† 19 1.9 103 1.0 1.83 1.12-3.01 1.62 0.96-2.73
Past use† 32 3.2 263 2.6 1.21 0.83-1.76 0.96 0.65-1.42
No use† 871 87 8691 87 Ref. Ref.*
Statin withdrawal with reference to current use of statins
Current use 82 8.2 976 9.7 Ref. Ref.§
Recent withdrawal 19 1.9 103 1.0 2.19 1.28-3.75 2.34 1.35-4.05
Simvastatin 5 0.5 41 0.4 1.44 0.56-3.73 1.51 0.58-3.92
Pravastatin 4 0.4 19 0.2 2.52 0.83-7.69 2.54 0.83-7.77
Fluvastatin 1 0.1 1 0.0 ‒
Atorvastatin 7 0.7 32 0.3 2.60 1.12-6.06 2.88 1.22-6.80
Cerivastatin 0 0 0 0.0 ‒
Rosuvastatin 2 0.2 10 0.1 ‒ ‒
Past use 32 3.2 263 2.6 1.45 0.94-2.23 1.42 0.92-2.20
No use 871 87 8691 87.0 1.20 0.94-1.53 1.23 0.95-1.58
† ‘current use’ = use at index date; ‘recent withdrawal’ = stopping up to 30 days before index date; ‘past 
use’ = cessation of drug use more than 30 days before index date; ‘no use’ = drug is never used. $ Statins 
are currently used shorter, resp. longer than three years. *Adjusted for having a history of cardio- or 
cerebrovascular disease and use of platelet aggregation inhibitors, nitrates, and RAS medication. § 
Adjusted for hypertension.
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Table 3. Interaction between use of statins and antihypertensives, prior CVD or gender 
on the association with SAH 
statin use Eff ect modifi er Cases
n (%)
Controls
n (%)
Odds ratio
(95% CI)
use of antihypertensive 
medication
Current use Current use   60 (6.0)  683 (6.8) Ref.*
Recent withdrawal Current use    6 (0.6)   40 (0.4) 1.75 (0.71-4.33)
Current use Recent withdrawal    1(0.1)   16 (0.2) ‒
Recent withdrawal Recent withdrawal    5 (0.5)   27 (0.3) 2.37 (0.77-7.29)
Current use Past use    5 (0.5)   89 (0.9) 0.70 (0.27-1.82)
Recent withdrawal Past use    5 (0.5)    8 (0.1) 6.77 (2.10-21.8)
Prior CVD
No use No CVD 788 (92.5) 8088 (92.1) ‒
Current use No CVD  39 (4.6)  472 (5.4) 0.76 (0.53-1.09)#
Recent withdrawal No CVD  10 (1.2)   60 (0.7) 1.76 (0.64-4.82)**
No use CVD  83 (54.6)  603 (48.1) ‒
Current use CVD  43 (28.3)  504 (40.2) 0.64 (0.37-1.12)#
Recent withdrawal CVD    9 (5.9)   43 (3.4) (0.98-4.49)**
Gender
No use Male 286 (85.6) 2752 (82.4) ‒
Current use Male  33(9.9)  445 (13.3) 0.67 (0.43-1.05)#
Recent withdrawal Male   6 (1.8)   45 (1.3) 1.82 (0.70-4.73)**
No use Female 585 (87.3) 5939 (88.7) ‒
Current use Female  49 (7.3)  531 (7.9) 0.77 (0.55-1.08) #
Recent withdrawal Female  13 (1.9)   58 (0.9) 2.69 (1.36-5.31) **
* reference is current use of statins and current use of antihypertensives for all categories, adjusted for 
use of platelet aggregation inhibitors, RAS drugs and nitrates. **compared to current use and adjusted 
for use of hypertensive drugs. #compared to no use and adjusted for use of platelet aggregation 
inhibitors, RAS drugs and nitrates
Misclassifi cation of the outcome was a concern in our study as there is no 
information on the overall PPV of the discharge diagnosis. We demonstrated that 
the PPV was quite good and unrelated to exposure. Since we could not validate 
all cases, outcome misclassifi cation due to inclusion of false positives is a fact 
but limited and non-diff erential, resulting in an att enuation of the association. 
SAHs that were fatal before reaching the hospital were not included in our 
study because of the nature of the hospitalisation database. Therefore the results 
cannot be generalized to these types of fatal SAH. Confounding by indication 
might play a role in studying relations between statins and SAH, especially when 
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evaluating potential benefi cial eff ects. For the withdrawal analysis we addressed 
confounding by indication by comparing withdrawers to current users instead 
of no users. For current use of statins we conducted several analyses to inspect 
healthy user eff ects: exclusion of prevalent users and stratifi cation for primary/
secondary prevention. Healthy user bias may explain at least part of the association 
between current use of statins and SAH. Hypertension is a known risk factor for 
SAH. In this study we did not have information on actual blood pressure; we took 
stopping antihypertensives as proxy. Recent studies show that non-adherence 
with antihypertensives is indeed associated with increased systolic blood pressure 
[74], which supports the assumption that patients who stopped have uncontrolled 
blood pressure.
 The observation that the withdrawal eff ect is specifi c for statins, and does not 
occur in other drugs, encourages us to think of it as a true association; were the 
withdrawal eff ect due to reversed protopathic bias or immeasurable time bias, the 
ORs would have increased for other drugs.
In conclusion, we found that statins are associated with SAH, the risk increases 
substantially in patients who stop their statins and this eff ect was particularly 
pronounced in patients who had also stopped anti-hypertensive drug use.
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3.2 Platelet aggregation inhibitors, vitamin K antagonists, and 
risk of subarachnoid haemorrhage
Background: Use of platelet aggregation inhibitors and vitamin K antagonists 
has been associated with an increased risk of intracranial haemorrhage (ICH). 
Whether use of these antithrombotic drugs is associated with an increased risk of 
subarachnoid haemorrhage (SAH) remains unclear, especially since confounding 
by indication might play a role.
Objective: Our aim was to investigate whether use of platelet aggregation 
inhibitors or vitamin K antagonists increase the risk of SAH. 
Methods: We applied population-based case-control, case-crossover, and case-
time-control designs to estimate the risk of SAH while addressing issues both of 
confounding by indication and time varying exposure within the PHARMO Record 
Linkage System database. This system includes drug dispensing records from 
community pharmacies and hospital discharge records of more than three million 
community dwelling inhabitants in the Netherlands. Patients were considered a 
case if they were hospitalised for a fi rst SAH (ICD-9-CM code 430) in the period 
between January 1st 1998 and December 31st 2006. Controls were selected from the 
source population, matched on age, sex, and date of hospitalisation. Conditional 
logistic regression was used to estimate multivariable adjusted odds ratios and 
95% CIs for the risk of SAH during use of platelet aggregation inhibitors or vitamin 
K antagonists. In the case-crossover and case-time-control designs we selected 11 
control periods preceding the index date in successive steps of one month in the 
past.
Results: 1004 cases of SAH were identifi ed. In the case-control analysis the 
adjusted odds ratio (OR) for the risk of SAH in current use of platelet aggregation 
inhibitors was 1.32 (95% CI: 1.02-1.70) and in current use of vitamin K antagonists 
1.29 (95% CI: 0.89-1.87) compared to no use. In the case-crossover analysis the ORs 
for the risk of SAH in current use of platelet aggregation inhibitors and vitamin K 
antagonists were 1.04 (95% CI: 0.56-1.94) and 2.46 (95% CI: 1.04-5.82), respectively. 
In the case-time-control analysis the OR for platelet aggregation inhibitors was 
0.50 (95% CI: 0.26-0.98) and for vitamin K antagonists 1.98 (95% CI: 0.82-4.76).
Conclusion: Use of platelet aggregation inhibitors was not associated with an 
increased SAH risk; the modest increase observed in the case-control analysis 
could be due to confounding. Use of vitamin K antagonists was associated with 
an increased risk of SAH. The increase was most pronounced in the case-crossover 
analysis and therefore cannot be explained by unmeasured confounding. Vitamin 
K antagonists should be prescribed cautiously in patients with known unruptured 
aneurysms. 
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Introduction
Non-traumatic subarachnoid haemorrhage (SAH) is a severe neurological disorder 
with relatively low incidence. SAH is caused by a ruptured aneurysm in 85 percent 
of patients [1]. Due to its occurrence at younger age and high case fatality, SAH 
causes more loss of productive life years than ischemic and haemorrhagic stroke 
[1]. The classical cardiovascular disease risk factors such as age, gender, family 
history, hypertension, and smoking are risk factors for SAH [1, 23]. Use of platelet 
aggregation inhibitors and oral anticoagulants (vitamin K antagonists) has both 
been associated with increased risk of intracranial haemorrhage (ICH) [28]. The 
indication for platelet aggregation inhibitors is mostly secondary prevention of 
cardiovascular and cerebrovascular disease. These share many risk factors with 
SAH and may therefore cause confounding by indication. Vitamin K antagonists 
are indicated mainly for prevention and therapy of thrombo-embolic events. A 
review on oral anticoagulants versus antiplatelet therapy for preventing stroke in 
patients with non-valvular atrial fi brillation and no history of stroke or transient 
ischemic att acks (TIA) showed a doubling of risk on ICH in oral anticoagulant users 
compared to users of platelet aggregation inhibitors [25]. This fi nding suggests 
that a diff erence in association might be expected, due to diff erent haemostatic 
mechanisms. It remains unclear whether and to what extent these antithrombotic 
agents are associated specifi cally with SAH, as this is regularly not separated out 
[25, 29]. A recent population based case-control study indicated an increased risk 
of SAH in users of platelet aggregation inhibitors, but the authors acknowledge 
the vulnerability of their study to residual confounding [75]. 
 To quantify the associations while addressing the issue of residual 
confounding, we applied case-control, case-crossover, and case-time-control 
designs in a population-based database.  
Patients and methods
Sett ing
Data were obtained from the PHARMO Record Linkage System (RLS) database. 
This includes drug-dispensing records from community pharmacies and hospital 
discharge records of more than three million community dwelling inhabitants 
of 50 demographically defi ned areas in the Netherlands. For all residents, the 
computerized drug-dispensing histories contain data concerning the dispensed 
drug, type of prescriber, dispensing date, dispensed amount, prescribed dosing 
regimens, and the legend duration of use (prescription length). All drugs are coded 
according to the Anatomical Therapeutic Chemical (ATC) Classifi cation [76]. The 
hospital records include detailed information concerning discharge diagnosis, 
procedures, dates of hospital admission and discharge, and discharge destination 
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or dying in the hospital before discharge. Diagnoses are classifi ed according to 
the International Classifi cation of Diseases, Ninth Revision, Clinical Modifi cation 
(ICD-9-CM). For a detailed description of the database, which is representative for 
the Dutch population, we refer to previous work [70].
Source population
The source population included all persons in the PHARMO RLS database who 
had at least three years of valid database history. Persons were followed from 
inception or start of the study period (January 1st, 1998) until transferral out of the 
database, death, diagnosis of SAH, or the end of the study period (December 31st, 
2006), whichever came fi rst. 
Cases and controls
Study outcome was hospitalisation for SAH, registered as primary diagnosis code 
430 according to ICD-9-CM, as recorded in the PHARMO RLS database. Patients 
were considered a case if they were hospitalised for SAH in the period between 
January 1st 1998 and December 31st 2006. Previously, we have reported on a small 
validation study, in which we demonstrated that the positive predictive value 
(PPV) of this discharge diagnosis was 88 percent [56]. 
Case-control design
For each case, a set of controls was obtained from the source population by 
means of incidence density sampling [77]. Controls had to be alive at the index 
date (calendar date of hospitalisation for SAH of the case), and have no history of 
SAH. A random sample of up to 10 controls was drawn from the set of all eligible 
controls, matched to the case on year of birth, sex, and index date. 
Case-crossover design
To control for suspected residual confounding by both measured and unmeasured 
factors that are stable over time (in our study, a one year period), we additionally 
performed a case-crossover study. In this design, the case acts as its own reference 
by its own past experience, instead of using matched external controls [78]. Thus, 
confounders (measured and unmeasured) that are stable over time in one person 
cancel out. As control periods, we selected the 11 periods preceding the index date 
in successive steps of one month in the past. 
Case-time-control design
In Figure 1, we show the changes in prescriptions rates for platelet aggregation 
inhibitors and vitamin K antagonists over the study period in the PHARMO RLS 
database. The strong time trend in user prevalence observed in this fi gure triggered 
the use of a case-time-control design, as this design accounts for time-trends in 
exposure prevalence that may act as confounder in a case-crossover design [79]. 
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This design includes both cases and controls (as defi ned for the case-control 
design). Each of them is considered twice, once for the case period and once for the 
control periods (as defi ned for the case-crossover design). Within each case subject, 
exposure frequencies from the case and control periods are compared through a 
matched odds ratio (OR), as in the case-crossover design. Among control subjects, 
the frequencies of exposure during the case period and the control periods are an 
estimate of the exposure distribution in the underlying cohort during diff erent 
periods of time, and therefore the matched odds ratio between periods measures 
the time trend in exposure. The case-time-control design is based on two main 
assumptions: 1) the case-crossover odds ratio is the product of the odds ratio due 
to the causal eff ect of the exposure on the outcome and the odds ratio due to the 
time trend in exposure prevalence, and 2) the latt er is the same among cases and 
controls. Thus, the case-time-control odds ratio is the case-crossover odds ratio 
divided by the time trend odds ratio.
Figure 1. Exposure prevalence: number of prescriptions per 1000 persons for platelet 
aggregation inhibitors and vitamin K antagonists per calendar year. Data from the 
PHARMO RLS database, 1998-2006.
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Study drugs and defi nition of exposure
The primary drugs of interest were platelet aggregation inhibitors and vitamin K 
antagonists (see ATC codes in appendix). Heparin was left  out of our analyses due 
to insuffi  cient numbers. Exposure data were obtained from drug dispensing fi les. 
For platelet aggregation inhibitors, duration of use was obtained by dividing the 
total amount of dispensed units by the prescribed amount per day. In the case-
control study, use was classifi ed as “no”, “current” (use at index date), “recent 
past” (stopped less than 30 days before index date), and “distant past” (stopped 
more than 30 days before index date). In sensitivity analyses the exposure window 
of current use was extended to use within seven or fourteen days preceding the 
index date. In the case-crossover and case-time-control studies, “distant past” 
was merged with “no” use, because of the one month period we chose as control 
period. Since the registered dosing regimen for vitamin K antagonists in the 
pharmacy may diff er from the tailored dosing regimen of the thrombosis service, 
we manually examined all prescription histories for the case-crossover study, since 
this design is sensitive to misclassifi cation of the duration of a prescription. 
Covariates
We considered diabetes mellitus, hypertension, and a history of vascular events as 
covariates. Use of insulin without a history of use of oral anti-diabetic agents was 
considered a proxy for having diabetes mellitus type I (DM I). Use of oral anti-
diabetic agents either or not followed by use of insulin was considered a proxy for 
having diabetes mellitus type II (DM II). In this study we did not have information 
on blood pressure but considered antihypertensive drug use as proxy. Use of 
anti-hypertensive agents was considered a proxy for being in a state of controlled 
hypertension. Past use of antihypertensive drugs was considered a proxy for being 
in a state of uncontrolled hypertension. A history of vascular events was defi ned 
by use of two or more prescriptions of nitrates or hospitalization for ischemic 
cardiovascular or cerebrovascular events (CVD) in a three year period preceding 
the index date. 
 We also studied SSRIs, NSAIDs, and COX-2 selective inhibitors, because of 
their potential eff ects on bleeding risk [80, 81]; and the pain and neuropsychiatric 
agents: tricyclic antidepressants (TCAs), benzodiazepines, antipsychotics, anti-
epileptics, and antimigraine drugs; as well as female sex hormones, antibiotics, 
and statins as these have been associated with vascular events [26, 56, 82].
Statistical analysis
We compared cases and controls with regard to demographic characteristics and 
drug use. Next, we applied conditional logistic regression analyses to matched 
case-control data, case-crossover data, and case-time-control data to estimate 
matched odds ratios and 95 percent confi dence intervals (95% CI) for the association 
between exposure to drugs and SAH risk. Analyses were performed with reference 
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to no use. In the adjusted model we included all factors that changed the risk 
estimate with more than 5 percent. For all three study designs we performed 
sensitivity analyses to examine the eff ect of extension of the exposure window on 
the observed associations. The periods of current use were extended to cessation of 
use up to seven and fourteen days before the index date. We examined interaction 
of the study drugs with antihypertensive drugs, statin withdrawal, long term (> 30 
days) use of platelet aff ecting drugs (NSAID, SSRI), or antibiotics which increase 
the dose/eff ect of vitamin K antagonists [83]. To examine whether a history of 
vascular events was an eff ect modifi er, we performed a stratifi ed analysis. In the 
case-crossover study we conducted an additional sensitivity analysis on exposure 
misclassifi cation by excluding case-controls sets with a small unexplained ‘gap’ in 
the prescriptions for vitamin K antagonists, since it might be that this gap does not 
represent a true interval of abstinence. 
 Analyses were performed using SPSS soft ware version 15.0 (Chicago, 
Ill., USA). A two-sided p-value of less than 0.05 was considered signifi cant. To 
avoid presentation of unstable estimates, association measures for products with 
exposure in less than 3 cases or 3 controls are not reported.
 
Results
Case-control analysis
Our study population comprised of 1004 cases of SAH and 10,033 matched 
controls. Due to matching on year of birth and gender, mean age and distribution 
of sex in cases and controls were the same (table 1). Past use of antihypertensive 
drugs increased the risk of SAH, OR=1.34 (95% CI: 1.10-1.62). Current use of 
NSAIDs and COX-2 selective inhibitors (coxibs) seemed to be associated with 
SAH risk. However, exclusion of recent starters of NSAIDs or coxibs reduced the 
associations, pointing to protopathic bias. Current use of SSRIs was found to be 
unrelated to SAH, OR=0.96 (95% CI: 0.67-1.40).
 Use of platelet aggregation inhibitors was associated with an increased risk 
of SAH in the case-control analysis: the adjusted OR was 1.32 (95% CI: 1.02-1.70) 
(table 2). Use of vitamin K antagonists seemed to increase the risk of SAH, although 
the association was not statistically signifi cant. The adjusted OR was 1.29 (95% CI: 
0.89-1.87) (table 2). Extension of the exposure window of current use to seven or 
fourteen days aft er the end of the prescription yielded higher point estimates for 
both platelet aggregation inhibitors and vitamin K antagonists. For the latt er, the 
association reached the signifi cance threshold in the fourteen days period.
 In the case-control analysis, we found no interaction between antihypertensive 
drugs, statin withdrawal, long term use of NSAIDs or SSRIs, or antibiotics and 
platelet aggregation inhibitors or vitamin K antagonists (data not shown). 
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Table 1. Characteristics of the cases and controls.
 Cases Controls OR 95% CI
N % N %
Total 1004 100 10033 100
Mean age (SD) (years) 58 (14) 58 (14) Matched
<50 years 293 29 2928 29
50-65 years 383 38 3828 38
>65 years 328 33 3277 33
Gender, female 670 67 6695 67 Matched
Diabetes mellitus I 12 1.2 84  0.8 1.42 0.77-2.62
Diabetes mellitus II 57 5.7 649  6.5 0.87 0.66-1.16
Antihypertensives1
Current use 254 25.3 2560 25.5 1.05 0.89-1.25
Recent past 20 2 231  2.3 0.91 0.57-1.46
Past use 152 15.1 1197 11.9 1.34 1.10-1.62
No CV event history 870 86.7 8868 88.4 1
History of CV events 152 15.1 1254 12.5 1.30 1.07-1.59
Current use of other drugs1
SSRI 32 3.2 335  3.3 0.96 0.67-1.40
NSAID 80 8 357  3.6 2.34 1.77-3.09
Use > 30 days 37 3.7 297 3 1.30 0.90-1.87
COX-2 selective inhibitors 13 1.3 56 0.6 2.35 1.27-4.36
Use > 30 days 7 0.7 43 0.4 1.65 0.74-3.70
TCA 10 1 117 1.2 0.85 0.44-1.64
Benzodiazepines 102 10.2 764 7.6 1.43 1.13-1.80
Use > 30 days 74 7.4 740 7.4 1.04 0.80-1.36
Anti-psychotics 10 1 119 1.2 0.83 0.44-1.59
Anti-epileptics 15 1.5 121 1.2 1.26 0.73-2.17
Antimigraine 6 0.6 23 0.2 2.69 1.09-6.60
Use > 30 days 2 0.2 20 0.2 -
Estrogens 15 1.5 142 1.4 1.05 0.61-1.80
Progesterone 3 0.3 68 0.7 0.42 0.13-1.35
Combinations of estrogens 
and progestin 77 7.7 676 6.7 1.29 0.96-1.74
Antibiotics 19 1.9 145 1.4 1.36 0.83-2.23
Statins 82 8.2 976 9.7 0.84 0.66-1.07
1 current use compared to no use
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Case-crossover analysis
In the study population of 1004 cases, the 1004 risk periods directly preceding the 
SAH were compared to 11,044 control periods occurring in successive steps of 
one month in the past. Use of platelet aggregation inhibitors was not associated 
with SAH in this design: OR= 1.04 (95% CI: 0.56-1.94). These fi ndings were not 
susceptible to changes in the risk period (table 2). Use of vitamin K antagonists 
was signifi cantly associated with SAH; the OR was 2.90 (95% CI: 1.27-6.65). 
Extension of the risk period showed similar ORs (table 2). Exclusion of cases 
with an unexplained ‘gap’ in the prescription regimen (due to misclassifi cation 
of duration due to thrombosis service regimens) did not change the associations 
materially (data not shown). 
Table 2. Case-control, case-crossover, and case-time-control analyses.
Current use Case-control Case-crossover Case-time-control
Cases Controls OR 95% CI OR2 95% CI OR2 95% CI
Platelet aggregation 
inhibitors
No use (any time prior) 810 8443 1 1 1
Use at index date 111 1032 1.321 1.02-1.70 1.04 0.56-1.94 0.50 0.26-0.98
Use at index or stopping 
for max. of 7 days 116 1059 1.34
1 1.04-1.71 1.07 0.58-1.97 0.53 0.27-1.02
Use at index or stopping 
for max. of 14 days 121 1079 1.37
1 1.07-1.75 1.09 0.60-2.00 0.54 0.28-1.05
Vitamin K antagonists
No use (any time prior) 909 9221 1 1 1
Use at index date 39 283 1.293 0.89-1.87 2.90 1.27-6.65 1.98 0.82-4.76
Use at index or stopping 
for max. of 7 days 40 292 1.38
3 0.97-1.96 2.78 1.22-6.31 1.97 0.82-4.71
Use at index or stopping 
for max. of 14 days 45 313 1.44
3 1.03-2.02 3.03 1.35-6.81 2.07 0.87-4.89
1adjusted for hypertension and statin use and for use of vitamin K antagonists; 2 estimates of platelet 
aggregation inhibitors are adjusted for use of vitamin K antagonists and vice versa; 3 adjusted for use of 
RAS medication and use of platelet aggregation inhibitors.
Case-time-control analysis
For all controls from our case-control analysis, we selected index periods and 
control periods, analogous to what was done to the cases in the case-crossover 
design. Analysis of these 10,033 index periods and 110,363 control periods yielded 
the time trend odds ratio. By dividing the case-crossover odds ratio by the time 
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trend odds ratio we obtained the case-time-control estimate of the SAH risk in our 
population. This is mathematically identical to exponentiate the diff erence of the 
betas. Confi dence intervals were calculated by exponentiate this diff erence plus 
or minus 1.96 times the square root of the sum of the squared standard errors of 
the case-crossover and time trend betas. For platelet aggregation inhibitors this 
OR was 0.50 (95% CI: 0.26-0.98) and for vitamin K antagonists 1.98 (95% CI: 0.82-
4.76) (table 2). Extension of the exposure windows did not change the odds ratios 
substantially. 
Discussion
In our study we applied three study designs to examine the association between 
use of antithrombotic drugs and the risk of SAH. The case-crossover and case-
time-control designs were applied to address the issues of residual confounding 
and time bias, respectively. We found consistently that use of vitamin K 
antagonists was associated with an increased risk of SAH; although the estimates 
and confi dence intervals varied. Use of platelet aggregation inhibitors was not 
associated with SAH in this study. The increased risk observed in the case-control 
design disappeared when confounding by indication was taken into account in the 
case-crossover design. The eff ect decreased even further when taking time varying 
exposure prevalence into account in the case-time-control design. The fi ndings for 
platelet aggregation inhibitors seem very susceptible to confounding and time 
bias. 
 Hence, our fi ndings suggest that there is no association between use of platelet 
aggregation inhibitors and SAH in the general population. Iso et al. reported on 
a doubled risk of SAH in female aspirin users [84]. However, this fi nding was 
based on only twelve cases and considered women using fi ft een or more tablets 
of aspirin (325 mg.) per week. Schmidt et al. reported on a case-control study 
indicating an increased risk of SAH in users of platelet aggregation inhibitors [75]. 
With regard to size and demographics, their study population was similar to ours. 
The odds ratios they found in their case-control study were also quite similar to 
what we found in our case-control analysis. Both studies point to a small increase 
in risk of SAH in platelet aggregation inhibitor users. Our study is an addition in 
two important aspects; fi rst, we investigated the eff ect of anticoagulants additional 
to platelet aggregation inhibitors, and secondly, we addressed issues related to 
confounding more thoroughly. Schmidt et al. alluded to residual confounding 
as alternative explanation but they did not address it further. We showed that 
residual confounding actually explained the observed increase in risk for platelet 
aggregation inhibitors. 
 Our fi ndings on vitamin K antagonists are in line with what one would expect 
based on similar fi ndings on ICH [25, 28, 29]. Due to their pharmacological action, 
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antithrombotic drugs could convert a ‘warning leak’ into a life-threatening, major 
rupture, but it is not self-evident that these drugs cause lesions or ruptures. In 
a reported series on aneurysmal SAH, anticoagulants indeed seemed to increase 
the extent of the bleeding. As a consequence of more severe initial bleeding, the 
risk of death or dependency in anticoagulated patients versus those not receiving 
anticoagulants was almost doubled [85]. Whether the observed association 
represents a causal relation between use of vitamin K antagonists and SAH cannot 
be established defi nitively based on our data. 
 Hypertension is a known risk factor for SAH [23]. In this study we did not 
have information on blood pressure but considered antihypertensive drug use as 
a proxy. Current use of antihypertensive drugs was not associated with SAH, as 
the blood pressure of these patients is likely to be fairly controlled. But patients 
who formerly used antihypertensive drugs are likely to suff er from uncontrolled 
blood pressure; recent studies show that non-adherence to antihypertensive 
therapy is associated with high systolic blood pressure [74]. Indeed, former use of 
antihypertensive drugs was associated with increased risk of SAH. 
 With regard to other potential associations reported in table 1, it is unlikely 
that they represent true associations. Although NSAIDs, coxibs, and anti-migraine 
medication have platelet or vascular eff ects, it is most likely that the reported 
associations are due to protopathic bias, i.e. this medication is used to treat a 
prodrome of the disease under investigation. In case of SAH these prodromes are 
most likely headache and neck pain due to a ‘warning leak’. This explanation is 
supported by the sub analyses in patients using these agents for more than 30 
days; in these patients the association could not be found which argues against a 
causal relation. 
 The main strengths of our study are the size and the quality of the prospectively 
registered pharmacy data, which allow for estimation of the eff ects of timing of 
drugs. Despite these strengths the results of this study should be seen in the light 
of its limitations, inherent to any observational study with non-randomly assigned 
intervention. Due to the use of a population-based database of healthcare records 
selection bias is unlikely. Information bias may occur on the level of outcome as 
well as on the level of exposure. Despite errors in exposure assessment due to 
non-compliance, information bias is likely to be non-diff erential since data were 
gathered prospectively without having knowledge of the hypothesis studied [72, 
73, 86]. Misclassifi cation of the outcome was a source of concern in our study as 
there is no information on the overall PPV of the discharge diagnosis. In a small 
validation study we demonstrated that the PPV of this discharge diagnosis was 
88 percent [56]. Disease misclassifi cation due to inclusion of false positive cases 
is therefore limited and most likely non-diff erential, resulting at most in a small 
att enuation of the association. The use of a registry-based approach renders our 
study vulnerable to potential confounders that are not covered by our database. In 
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the case-control design we could not adjust for lifestyle factors such as smoking, 
alcohol abuse, obesity, and actual blood pressure. 
 But we addressed this residual confounding by conducting a case-crossover 
design. We considered application of the case-crossover design appropriate due 
to the nature of the association under investigation. The case-crossover design 
is particularly suitable when the exposure is intermitt ent, the eff ect on risk is 
immediate and transient, and the outcome is abrupt [78]. The outcome SAH fulfi ls 
the requirement of abruptness. The eff ect of antithrombotic drugs on bleeding 
tendency is in the order of magnitude of hours aft er administration, and the eff ect 
decreases in two to six days. The exposure to antithrombotic drugs is intermitt ent 
in the sense that the administration can be stopped and started at any moment, 
especially for vitamin K antagonists. 
 The case-time-control design was applied because of the time varying 
exposure prevalence of both platelet aggregation inhibitors and vitamin K 
antagonists (Figure 1).
 Of note is that the benefi cial eff ects of well-indicated antithrombotic drugs 
in appropriate patients should not be disregarded. However, any benefi ts could 
be off set by an increased risk of haemorrhages [87]. This may be the case in sub 
groups of high risk patients – patients harbouring an unruptered intracranial 
aneurysm, for instance. In those patients caution might be warranted with regard 
to prescribing vitamin K antagonists.
 Our results are of clinical relevance for the growing patient group with a 
recent TIA or minor stroke in whom a work-up for carotid or intracranial stenosis 
reveals an intracranial aneurysm [88]. Our results suggest that platelet aggregation 
inhibitors can be prescribed safely to these patients.
In conclusion, use of platelet aggregation inhibitors was not associated with an 
increased SAH risk; the modest increase observed in the case-control analysis 
could be due to confounding. Use of vitamin K antagonists was associated with 
an increased risk of SAH in some designs. The increase was most pronounced 
in the case-crossover analysis and therefore cannot be explained by unmeasured 
confounding. Vitamin K antagonists should be prescribed cautiously in patients 
with known unruptured aneurysms. 
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Appendix
Platelet aggregation inhibitors:
All B01AC drugs were eligible, in PHARMO only the following drugs in this class 
were used during the study period: B01AC04 (clopidogrel), B01AC05 (ticlopidine), 
B01AC06 (acetylsalicylic acid), B01AC07 (dipyridamole), B01AC08 (carbasalate 
calcium), B01AC30 (combinations). 
Vitamin K antagonists: 
All B01AA drugs were eligible, in PHARMO only the following drugs in this 
class were used during the study period: B01AA04 (phenprocoumon), B01AA07 
(acenocoumarol).
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3.3 Oral contraceptives and risk of subarachnoid haemorrhage
Background: The question whether use of oral contraceptive pills (OCP) aff ects the 
risk on (aneurysmal) subarachnoid haemorrhage (SAH) is relevant since female 
sex as a risk factor for SAH changes aft er menopause. 
Objective: To estimate the association between OCP use and the risk of 
(aneurysmal) SAH.
Methods: We conducted population-based case-control studies in two diff erent 
databases in the Netherlands. One was the PHARMO Record Linkage System 
database which includes drug dispensing records from community pharmacies 
and hospital discharge records of more than three million community dwelling 
inhabitants in the Netherlands. The second was the Integrated Primary Care 
Information (IPCI) database, a database with longitudinal medical records of 
currently more than one million persons. We identifi ed cases from these two non-
overlapping populations. In PHARMO a case was defi ned as a female under age of 
50 years hospitalised for SAH (ICD-9-CM code ‘430’) in the period 01.01.98-12.31.06. 
Ten randomly chosen controls were matched to each case on age, sex, and index 
date. In IPCI, cases were females below 50 years with a validated aneurysmal SAH. 
All eligible controls, obtained from the source population by means of incidence 
density sampling, were matched to the case on age, sex, and index date.
Results: In PHARMO the odds ratio (OR) for the SAH risk in OCP users was 1.79 
(95% CI: 1.22-2.64). Subdivision according to progestin content of the OCP showed 
an OR for levonorgestrel use of 1.88 (95% CI: 1.24-2.85) and for desogestrel 1.99 
(95% CI: 1.11-3.54). In IPCI the results were very similar; the OR for OCP use was 
2.11 (95% CI: 0.82-5.42). The OR for levonorgestrel use to 3.19 (95% CI: 1.20-8.48).
Conclusions: Use of OCP seems to be associated with an increased risk of 
(aneurysmal) SAH.
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Introduction
Subarachnoid haemorrhage (SAH) is a severe neurological disorder. Due to its 
occurrence at younger age and its higher case fatality, SAH causes more loss 
of productive life years than ischemic and haemorrhagic stroke, although its 
incidence is much lower [1]. Ruptured aneurysms are the cause of the SAH in 
approximately 85 percent of patients [1]. 
Non-modifi able risk factors such as age, sex, and family history play an important 
role in the risk of SAH [1, 23]. Modifi able risk factors have been identifi ed as well, 
providing opportunities for intervention. Established modifi able risk factors for 
SAH are hypertension, smoking, and excessive alcohol intake [1]. Another class 
of potentially modifi able risk factors comprises the use of drugs, but their role in 
SAH aetiology has not been systematically evaluated. The fact that the age-specifi c 
incidence rate of SAH is higher in postmenopausal women than in men, but lower 
in premenopausal women than men suggests an infl uence of sex hormones [2]. 
In addition, endothelium-dependent arterial vasodilatation increases signifi cantly 
during the ovulatory phase of the menstrual cycle, when oestrogen levels are 
highest in naturally cycling young women [89-91], and some progestins may 
antagonize the benefi cial vascular eff ects of oestrogen in postmenopausal women 
[92-95]. Each progestin can have diff erent eff ects on the vasculature depending 
on the parent molecule from which it was created, its chemical structure, 
pharmacokinetics, activity and specifi city to given receptors [96-98]. 
 Several studies on the association between use of OCP and the risk of 
subarachnoid haemorrhage in premenopausal women have been conducted. 
Results of these previous investigations were inconclusive; a meta-analysis and 
a systematic review led to contradictory conclusions [23, 26]. The meta-analysis 
of observational studies by Johnston et al. suggests that OCP use produces a 
small increase in the risk of SAH [26]. The systematic review by Feigin et al. [23] 
considered only one extra study with regard to OCP use (Mhurchu et al. [6]), 
which showed no eff ect of OCP use on SAH risk. The conclusion of the systematic 
review was that use of OCP does not signifi cantly aff ect the risk of SAH [23]. These 
overviews did not examine the eff ect of diff erent progestin contents. Additionally, 
the study of Mhurchu et al. dichotomised the OCP group in ‘ever users’ and ‘never 
users’ which may result in severe misclassifi cation and inability to demonstrate an 
eff ect [6].
 To investigate the association between SAH and OCP use, and specifi cally 
the progestin contents of OCP, we conducted two population-based case-
control studies. We were interested in SAH in general and more specifi cally in 
aneurysmal SAH. The fi rst study was performed in a discharge database linked to 
drug dispensing records (PHARMO). The second in an electronic medical record 
database (IPCI). The latt er database was smaller, but allowed for more detailed 
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validation of aneurysms as the underlying cause of rupture. During the study 
period the databases did not overlap in their underlying source population.
Patients and methods
Sett ing
Data were obtained from the PHARMO Record Linkage System (RLS) and the 
Integrated Primary Care Information database (IPCI). 
PHARMO RLS includes, amongst other databases, the drug-dispensing records 
from community pharmacies and hospital discharge records of more than three 
million community dwelling inhabitants of 50 demographically defi ned areas in 
the Netherlands. 
 For all residents, the computerized drug-dispensing histories contain data 
concerning the dispensed drug, type of prescriber, dispensing date, dispensed 
amount, prescribed dosing regimens, and the legend duration of use (prescription 
length). All drugs are coded according to the Anatomical Therapeutic Chemical 
(ATC) classifi cation [99]. The hospital records include detailed information 
concerning diagnoses, procedures, and dates of hospital admission and discharge. 
All diagnoses are coded according to the International Classifi cation of Diseases, 
Ninth Revision, Clinical Modifi cation (ICD-9-CM). For a detailed description of the 
database, which is representative for the Dutch population, we refer to previous 
work [70]. 
 The Integrated Primary Care Information (IPCI) database is a general practice 
research database with electronic medical record data currently comprising more 
than one million patients throughout the Netherlands. This patient population is 
representative of the general Dutch population regarding age and sex [50]. In the 
health care system in the Netherlands, everyone is registered with one general 
practitioner who is the gatekeeper for medical care and information. The electronic 
records contain anonymous and coded information on patient demographics, 
symptoms and diagnoses (using the International Classifi cation for Primary Care 
(ICPC-codes [100]) and free text terminology), referrals, clinical and laboratory 
fi ndings, and hospitalizations. Summaries of hospital discharge lett ers or additional 
information from medical specialists are entered in a free text format and hard 
copy lett ers can be requested. Information on drug prescription comprises brand 
name, amount, strength, indication, prescribed daily dose and the Anatomical 
Therapeutic Chemical (ATC) classifi cation. To maximize completeness of the data, 
GPs participating in the IPCI project are required not to use paper-based records 
in addition. The system complies with European Union guidelines on the use of 
medical data for research and is valid for pharmaco-epidemiological research [51]. 
The Scientifi c and Ethical Advisory Group of the IPCI project approved the study 
(Project No. 07/02).
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Source population
In PHARMO the source population included all females who had at least three 
years of valid database history and were 50 years of age or younger. Because of our 
research interest in OCP we were primarily interested in premenopausal women. 
Since the mean age of menopause is 51 year, a maximum age of 50 was chosen 
[101]. Persons were followed from inception or start of the study period (January 
1st, 1998) until transferral out of the database, death, diagnosis of SAH, or the end 
of the study period (December 31st, 2006), whichever came fi rst.
 In IPCI the source population comprised females below 50 years of age, with 
at least 1 year of valid history in the IPCI database during the study period (January 
1996-September 2006). Follow-up started at the beginning of the study period or 
on the date on which 1 year of valid history was available, whichever date was 
latest. Follow-up was terminated when the person transferred out of the practice, 
turned 50 years of age, the date of last data supply by the GP, death, diagnosis of 
SAH or at the end of the study period, whichever came fi rst. 
Cases and controls
In the PHARMO database the study outcome was hospitalisation for a fi rst SAH. 
Cases were females hospitalised for the fi rst SAH during the study period, as 
recorded in the Dutch National Medical Registration (LMR) with ICD-9-CM code 
430. For each case a set of controls was obtained from the source population by 
means of incidence density sampling [77]. Controls had to be alive at the index 
date (calendar date of hospitalisation for SAH of the case) and have no history of 
SAH. A random sample of up to 10 controls was drawn from the set of all eligible 
controls, matched to the case on year of birth, sex, and index date.
 In IPCI, cases were female patients under the age of 50 with an aneurysmal 
SAH confi rmed by lumbar puncture, neuroradiological investigation, surgery, 
or autopsy. Potential cases were identifi ed from the computerized records by 
searching for ICPC codes and free text searches. The computerized medical records 
of all potential cases were manually evaluated by a medical doctor (RR) to exclude 
false positive records and to assess the date of occurrence of the subarachnoid 
haemorrhage (index date). For all remaining cases specialist lett ers were requested 
from the GP. These lett ers were evaluated by two medical doctors (RR, DD). Each 
case was either classifi ed as defi nite or excluded. Patients with subarachnoid 
haemorrhage originating from a source other than an intracranial aneurysm, were 
excluded; patients with proven SAH in whom an aneurysm could not be identifi ed 
were also excluded. The doctors were blinded to drug exposure throughout the 
validation process. For each case a set of controls was obtained from the source 
population by means of the incidence density sampling method [77]. Women 
with a suspected, though unproven SAH or with a SAH of unknown origin were 
censored at the date of diagnosis and were ineligible as controls thereaft er. All 
eligible controls were matched to the case on year of birth, sex, and index date. 
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Study drugs and defi nition of exposure
The group of drugs of primary interest were oral contraceptive pills (OCP). Drug 
prescriptions were obtained from dispensing fi les (PHARMO) or prescription fi les 
(IPCI). The dosage of a prescription or dispensing was calculated based on the 
strength of one unit and prescribed dosing regimen. Duration of use was obtained 
by dividing total number of dispensed units by prescribed number per day while 
taking into account the stop weeks. OCP use was classifi ed as ‘no use’, ‘current 
use’ (use at index date or within 90 days previous [102]), and ‘past use’ (cessation 
of drug use more than 90 days before index date). 
 To investigate diff erences in eff ects we also classifi ed the exposure categories 
of OCP according to their progestin content.
Covariates
We considered diabetes mellitus (DM) and concomitant use of other medications 
as covariates. Antihypertensive agents were studied as a proxy for hypertension. 
We also studied agents known for increased bleeding risk (antithrombotics and 
SSRI), as well as NSAID, coxibs, tricyclic antidepressants (TCA), benzodiazepines, 
antibiotics, anti-migraine drugs, systemic corticosteroids, and statins (table 1).
Statistical analysis
Analyses were performed using SPSS soft ware version 15.0. (Chicago, Ill., USA). 
A two-sided P-value of less than 0.05 was considered signifi cant. The two case-
control studies were analysed separately.
 First, we compared cases and controls with regard to demographic 
characteristics and drug use. Next, we used conditional logistic regression analysis 
for matched case-control data to estimate matched odds ratios (OR) and 95 percent 
confi dence intervals (95% CI) for SAH associated with drug exposure. All analyses 
were performed with reference to no use. Factors that changed the eff ect estimate 
of OCP use with more than 5 percent were considered confounders. 
 To examine the impact of alternative defi nitions of the exposure window, 
sensitivity analyses were conducted that considered various time intervals for 
current use (use up to 30, 60, 90, 120, and 150 days). 
 To avoid presentation of unstable estimates, association measures for products 
with exposure in less than 3 cases or 3 controls are not reported.
Results
The PHARMO study population comprised of 218 cases with a SAH and 2,179 
matched controls. Mean age of the cases was 42 years (standard deviation [SD]: 
6 years). Past use of antihypertensives was associated with an increased risk of 
SAH (table 1). NSAIDs, coxibs, and benzodiazepines increased the risk. However, 
50 | Chapter 3
exclusion of recent starters weakened the eff ect, which points to protopathic bias 
(data not shown), similarly to what was demonstrated in a previous paper [56]. 
Use of antibiotics or systemic corticosteroids increased the risk of SAH. Odds 
ratios were 2.17 (95% CI: 1.16-1.54) and 3.17 (95% CI: 1.13-8.92), respectively. Most 
of the covariates had a very low prevalence in this young female population and 
none was found to be a confounding factor. 
 Use of OCP was associated with an increased SAH risk. The odds ratio was 
1.79 (95% CI: 1.22-2.64). Subdivision according to progestin content of the OCP 
showed increased risk in current users of levonorgestrel or desogestrel containing 
OCP. The odds ratio for levonorgestrel use up to 90 days before index date was 1.88 
(95% CI: 1.24-2.85), for desogestrel 1.99 (95% CI: 1.11-3.54) (table 2). Use of OCP 
containing gestodene or cyproteron was not statistically signifi cantly associated 
with risk of SAH. Other progestins (lynestrenol, norethisterone, norgestimate, 
drospirenone, norelgestromin) could not be studied separately due to insuffi  cient 
numbers.
 In table 3 we present the odds ratios for current use of oral contraceptive pills 
while considering current exposure up to 30, 60, 90, 120, and 150 days before the 
date of SAH; the estimates were quite stable.
The IPCI study population comprised of 26 cases with an aneurysmal SAH and 
46,667 controls. Mean age was 40 years (SD: 7 years); slightly younger than the 
SAH cases in PHARMO. Most covariates had very low prevalence in these young 
females and we could not estimate the associations reliably (table 1). Use of 
NSAIDs and benzodiazepines were strongly associated with aSAH risk, with ORs 
of 5.01 (95% CI: 1.60-15.7) and 7.65 (95% CI: 2.69-21.7), respectively. These fi gures 
are likely caused by protopathic bias. 
 OCP use was associated with an increased SAH risk, although not statistically 
signifi cant. The odds ratio was 2.11 (95% CI: 0.82-5.42). Subdivision by progestin 
content showed a strong association between aSAH and levonorgestrel use 
(OR=3.19 [95% CI: 1.20-8.48]). Other progestins could not be studied due to small 
sample size (table 2). 
 The strength of the eff ect estimate for overall OCP use did not vary a lot when 
the risk window was changed below or beyond 90 days (table 3).
Discussion
In our population based studies we found that OCP use was associated with an 
increased risk of SAH in women less than 50 years of age. Sensitivity analyses 
showed stable point estimates for diff erent exposure windows that were included 
in the current user group. The eff ect was most pronounced in levonorgestrel 
and desogestrel containing OCP. For the fi rst progestin the increased risk was 
confi rmed for aneurysmal SAH in the IPCI database. 
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Table 3. Odds ratios for OCP and SAH risk with current use up to 30, 60, 90, 120, and 150 
days before index date.
PHARMO IPCI
Days n OR CImin CImax n OR CImin CImax
30 75 1.59 1.07 2.36 10 2.08 0.80 5.43
60 86 1.70 1.15 2.51 10 1.99 0.76 5.20
90 93 1.79 1.22 2.64 11 2.11 0.82 5.42
120 93 1.75 1.19 2.57 11 2.03 0.79 5.22
150 96 1.75 1.20 2.57 12 2.16 0.85 5.45
The exact mechanism for the association between OCP use and (aneurysmal) 
SAH is not known, but several explanations for a relation between OCP use and 
physiological changes leading to increased vascular risk have been postulated [31, 
103]. Endothelium-dependent vasodilatation was found to be reduced in users of 
OCP containing levonorgestrel [103]. Others concluded that OCP use promotes 
endothelial dysfunction [31]. Furthermore, exposure to exogenous sex hormones 
leads to alterations in large arterial wall stiff ness, due to changes in elastin and 
collagen deposition [104, 105]. In large vessels, these changes increase the risk 
of deformations and dissection or rupture. Analogously, in cerebral arteries this 
mechanism might lead to higher susceptibility for SAH [106]. 
  Another important potential pathway is increased blood pressure which 
is a known risk factor for (aneurysmal) SAH. OCP use has been shown to 
increase blood pressure [107, 108]. In particular levonorgestrel containing OCP is 
mentioned in relation with increased blood pressure [109, 110]. Increased blood 
pressure could act as an intermediate factor in the association between OCP and 
(aneurysmal) SAH. A more than ten-fold increase in haemorrhagic stroke risk has 
been described in women with a history of hypertension who used OCP [102].
Strengths and limitations
The main strength of our study was that we used two population based databases 
which had detailed information on medication (brand name, amount, strength, 
indication, prescribed daily dose and the Anatomical Therapeutic Chemical 
classifi cation code) both for cases and controls. In addition, our study had a case-
control design, in which cases and controls were selected from dynamic cohorts. 
This implies that selection bias is unlikely as all cases and controls came from the 
same source population. Because data were collected prospectively and without 
knowledge of the research hypothesis to be studied, information bias is also 
highly unlikely. We also consider age matching as an important tool to compare 
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women of similar age to escape problems concerning cohort eff ects and att rition 
of susceptibles. 
 Despite these strengths, the results of this study should be seen in the light 
of its limitations which are inherent to any observational study with non-random 
treatment assignment. In PHARMO, misclassifi cation of the outcome was a concern 
as there is no information on the overall positive predictive value (PPV) of the 
discharge diagnosis. In a previous study we showed that the PPV was reasonable, 
which would lead to only small misclassifi cation [56]. In IPCI, misclassifi cation 
of the outcome is minimal as we manually validated all cases and only analyzed 
defi nite aneurysmal SAH cases. 
 There are several known risk factors that we could not fully capture by the 
data provided by the healthcare databases. Important factors are: menopause, 
alcohol intake, hypertension, and smoking. Confounding by menopause was 
limited through age restriction (< 50 years) and matching on age. Alcohol use and 
smoking could not be accurately obtained from the databases, but it is unlikely 
that alcohol intake is related to prescription of OCPs and the type of progestin. 
Smoking is a relative contra-indication for OCP use, because of the thrombotic 
risk. Residual confounding by smoking may result in an underestimation of the 
risk.
 Odds ratios of about 2 for a rare event have limited clinical importance or 
public health signifi cance, but the fact that the progestin type may impact and 
is variable among OCPs may be taken into account when prescribing OCPs, 
especially when women are known to have an intracranial aneurysm [111]. 
 In conclusion, this study shows that OCP use is associated with SAH, but that 
the risk varies by progestin content. Women with known intracranial aneurysms 
should consider avoiding OCPs.
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3.4 Genome-wide association study of intracranial aneurysm 
identifi es three new risk loci
Saccular intracranial aneurysms are balloon-like dilations of the intracranial 
arterial wall; their hemorrhage commonly results in severe neurologic impairment 
and death. We report a second genome-wide association study with discovery 
and replication cohorts from Europe and Japan comprising 5,891 cases and 14,181 
controls with ~832,000 genotyped and imputed SNPs across discovery cohorts. We 
identifi ed three new loci showing strong evidence for association with intracranial 
aneurysms in the combined dataset, including intervals near RBBP8 on 18q11.2 
(odds ratio (OR) = 1.22, P = 1.1 × 10-12), STARD13-KL on 13q13.1 (OR = 1.20, 
P = 2.5 × 10-9) and a gene-rich region on 10q24.32 (OR = 1.29, P = 1.2 × 10-9). We also 
confi rmed prior associations near SOX17 (8q11.23-q12.1; OR = 1.28, P = 1.3 × 10-12) 
and CDKN2A-CDKN2B (9p21.3; OR = 1.31, P = 1.5 × 10-22). It is noteworthy that 
several putative risk genes play a role in cell-cycle progression, potentially 
aff ecting the proliferation and senescence of progenitor-cell populations that are 
responsible for vascular formation and repair.
 Intracranial aneurysms aff ect approximately 2% of the general population 
and arise from the action of multiple genetic and environmental risk factors 
[12]. We previously reported the fi rst genome-wide association study (GWAS) 
of intracranial aneurysms [34] that identifi ed three risk loci on chromosomes 
8q11.23-q12.1, 9p21.3 and 2q33.1 with P < 5 × 10-8. This previous study had limited 
power to detect loci imparting genotypic relative risk (GRR) < 1.35. 
 To increase the power to detect additional loci of similar or smaller eff ect, 
we ascertained and whole-genome genotyped two new European case cohorts 
(n = 1,616) and collected genotyping data from fi ve additional European control 
cohorts. We also increased the size of the original Japanese replication cohort and 
added a new one (2,282 aff ected individuals (cases) and 905 controls) (Table 1). The 
new combined cohort had nearly threefold more cases than the original cohort and 
increased our power to detect variants with modest eff ect sizes. For example, this 
study had 89% and 64% average power to detect common variants (minor allele 
frequencies (MAF) ≥ 10%) with GRR of 1.25 and 1.20, respectively.
 All subjects were genotyped using the Illumina platform. The new as well 
as the previously analyzed genotyping data were subjected to well-established 
quality-control measures. We sought to eliminate potential confounding due to 
population stratifi cation and gender [12, 112] by matching cases and controls of the 
same gender based on inferred genetic ancestry. As previous studies demonstrated 
that the Finnish population forms an ancestry cluster distinct from other European 
populations similar to those included in this study [113, 114], we analyzed our 
Finnish cohort independently from the others. To maximize opportunities for 
genetic matching and analytic power, we analyzed all subjects in the remaining 
European cohorts together. The resulting matched case-control data consisted 
56 | Chapter 3
of 808 cases and 4,393 controls in the Finnish cohort and 1,972 cases and 8,122 
controls in the rest of the combined European cohort. We used the genotype data 
that passed quality-control fi lters and phased chromosomes from the HapMap 
CEU sample to impute missing genotypes [115]. We based our further analyses 
on 831,534 SNPs that passed the quality-control fi lters both in the Finnish and 
European samples (Table 1).
Table 1. Overview of the study cohorts.
Cohort Case (n) Control (n)
Quality 
control-passed
SNPs (n) GIF
Discovery Finland (FI) 808 4,393 1,303,876 1.074
Combined European (CE) 1,972 8,122 905,906 1.094
total discovery 2,780 12,515 831,532 1.007
CE subcohorts NL 708 3,954 905,906 1.108
DE 789 2,228 905,906 1.059
AN 475 1,940 905,906 1.057
Replication Japan 1 (JP1) 829 761 12
Japan 2 (JP2) 2,282 905 13
total replication 3,111 1,666 12
Total 5,891 14,181 12
Combined European cohort consisted of all European subjects who were not ascertained in Finland. Sub-
cohorts of the European cohort were defi ned on the basis of case series; NL, cases from The Netherlands 
with matched controls; DE, German cases with matched controls; AN, @neurIST cases with matched 
controls. NL, DE and AN were exclusive subsets of the European cohort (see also Supplementary Table 
3). AN cases consisted of subjects from Germany, Great Britain, Hungary, The Netherlands, Switzerland 
and Spain. JP1 and JP2 were two independent Japanese case-control cohorts. Genomic infl ation factors 
of the Finnish and European cohorts (as well as NL, DE and AN) were calculated for 1,303,876 and 
905,906 SNPs, respectively. The genomic infl ation factor of the discovery cohort (total discovery) was 
based on the meta-analysis result for 831,532 SNPs aft er correcting each cohort for genomic control. The 
discovery data (combined Finnish and European cohorts) was not corrected for genomic control. GIF, 
genomic infl ation factor.
 We tested for association of each quality control–passed SNP with intracranial 
aneurysms using conditional logistic regression, assuming a log-additive eff ect of 
allele dosage. We corrected each cohort for residual overdispersion (Table 1) using 
genomic control [116] and combined the results from the Finnish and European 
cohorts to obtain P values, ORs and CIs for the discovery cohort of 2,780 cases and 
12,515 controls using a fi xed-eff ects model.
 To evaluate the strength of association, in addition to obtaining P values, we 
employed a Bayesian approach [117]. We used the Bayes factor that represents the 
fold-change of the odds of association before and aft er observing the data [118] 
and the posterior probability of association (PPA), calculated through the Bayes 
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factor, that provides a simple probabilistic measure of the evidence of association 
[117, 119]. For every SNP, we assumed a uniform prior probability of association 
of 1/10,000 and set the prior of the logarithm of the per-allele OR as a normal 
distribution with a 95% probability for the OR to be between 0.67 and 1.5, with 
larger weights for smaller eff ect sizes [118, 120].
 From the discovery results, we eliminated two imputed SNPs that showed 
PPAs of 0.97 and 0.94 because their association signals were not supported by 
surrounding genotyped SNPs and because their genotypes were not confi rmed 
by direct genotyping results (data not shown). This resulted in 831,532 SNPs that 
passed quality control.
 We observed three regions that showed very high PPAs (>0.995; Figure 1a) 
and also a substantial excess of SNPs with P < 1 × 10−3 (1,295 SNPs versus 831 
SNPs expected by chance) even aft er excluding those within previously identifi ed 
associated regions [34] (Figure 1b). Moreover, we observed a strong correlation 
between the P values and Bayes factors for the upper tail of the distribution (Figure 
1c).
 We focused on fi ve genomic regions (Figure 1a) that contained at least one 
SNP with PPA > 0.5 for which the hypothesis of association with intracranial 
aneurysm was more likely than the null hypothesis of no association. The PPAs of 
the most highly associated SNPs in these intervals ranged from 0.6621 to > 0.9999 
and the P values ranged from 7.9 × 10−7 to 2.2 × 10−16. The fi ve chromosomal 
segments included three newly identifi ed SNP clusters on 10q24.32, 13q13.1 and 
18q11.2. The remaining two regions were previously identifi ed loci on 8q11.23–
q12.1 and 9p21.3 (Figure 2; ref. 2). The third locus identifi ed in our previous study, 
on 2q33, did not contain any SNPs with PPA > 0.5. Furthermore, consistent with 
our previous results [34], detailed analysis of the 8q11.23–q12.1 region detected 
two independent association signals within the < 100-kb interval that spans the 
SOX17 locus (Fig. 2); these two signals are hereaft er referred to as 5′-SOX17 and 
3′-SOX17. Thus, the fi ve chromosomal segments comprised six independent 
association signals for follow-up.
 We performed replication genotyping in two Japanese cohorts including 
3,111 cases and 1,666 controls (JP1 and JP2, see Table 1). For each independent 
signal, we selected for replication the genotyped SNP with the highest PPA and 
added up to two additional SNPs per locus. For the 5′-SOX17 region, we selected 
two SNPs analyzed previously, as they tag the most signifi cant SNP in the current 
study.
 All but one of the SNPs (rs12411886 on 10q24.32 in JP1) were successfully 
genotyped and passed quality-control fi lters. We tested for association of each 
SNP with intracranial aneurysm using logistic regression stratifi ed by gender, 
specifying the same model as for the discovery cohort. We combined results from 
JP1 and JP2 using a fi xed-eff ects model (Table 2). We considered an association 
to be replicated if the Bayes factor increased the odds of association more than 
tenfold aft er the replication data was observed.
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Figure 1. Genome-wide association analysis results in the discovery cohort. (a) 
The PPAs for 831,532 quality control–passed SNPs that were analyzed specifying a prior 
probability of association of 1/10,000 are plott ed against genomic locations of SNPs. A 
gray horizontal line at PPA = 0.5 indicates the cutoff  value for follow-up genotyping. (b) 
Quantile-quantile plots of P values (−log10 scale) are shown for all the SNPs analyzed 
(black; n = 831,532); for SNPs aft er excluding those within previously identifi ed regions 
(red; n = 830,907); and for SNPs aft er excluding all within the fi nal associated intervals 
(blue; n = 830,158). (c) A scatt er plot of −log10 P versus log10 Bayes factors is shown with 
color for each point indicating the range of PPA values. There are very close relationships 
among the P values for association, the Bayes factor and the PPA value. Note that, given 
a uniform prior probability of association, the PPA increases as the Bayes factor increases. 
A vertical line indicates the minimum PPA threshold at 0.5 (Bayes factor = 1.0 × 104) for 
follow-up.
 Of the six candidate loci, all but the 5′-SOX17 interval were replicated, with 
replication P values ranging from 0.0019 to 1.0 × 10-7, and the odds of association 
with intracranial aneurysm increasing by 22.9-fold to 1.5 × 105-fold, yielding robust 
evidence for replication for each interval (Table 2).
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Figure 2. Regional plots for associated regions. For each chromosomal interval, −
log10 P values for association are plott ed against the genomic coordinates (NCBI build 
36) in the panel above; the recombination rates obtained from the HapMap database 
and the RefSeq genes (hg18) within the regions are shown in the panel below. Above, 
rs identifi ers of SNPs listed in table 2 are shown and their positions are indicated by 
gray vertical lines. Gray dashed lines indicate locations of other SNPs genotyped in the 
replication cohorts. Dark blue and light blue dots represent results of genotyped and 
imputed SNPs for the discovery cohort, respectively; orange and light orange squares 
represent association results for the replication cohort using JP1 combined with JP2 and 
also JP2-only, respectively; combined results for SNPs genotyped both in the discovery 
and the replication cohort using JP1 plus JP2 and JP2-only are shown by red and light red 
diamonds, respectively.
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 We combined the discovery and replication results using a fi xed-eff ects 
model. All of the fi ve loci that replicated in the Japanese cohort surpassed the 
conventional threshold for genome-wide signifi cance (P < 5 × 10-8), with P values 
ranging from 2.5 × 10-9 to 1.5 × 10-22, and all also had PPAs ≥ 0.998 (Table 2).
 In order to determine each cohort’s contribution to the observed association 
and to assess the consistency of the eff ect size across groups, we analyzed each 
of them separately (Table 1) and then combined the results from the six cohorts 
using a random-eff ects model. The association results remained highly signifi cant 
(Figure 3). For the fi ve loci that were replicated in the Japanese cohorts, we found 
no evidence of signifi cant heterogeneity (P > 0.1). Every cohort had the same risk 
allele and provided support for association with the exception of the JP1 sample 
for the 3′-SOX17 locus, consistent with our previous study [34] (Figure 3).
Figure 3. Consistency of association across cohorts. Forest plots are shown for meta-
analysis of the SNPs listed in table 2. Squares and horizontal segments represent 
estimated per-allele ORs and 95% CIs for individual cohorts. Diamonds represent the 
summary OR estimates and 95% CIs for the meta-analyses of six cohorts (using fi xed- and 
random-eff ects models). Log10 (Bayes factor) > 0 supports association with intracranial 
aneurysm, whereas log10 (Bayes factor) < 0 supports no association with intracranial 
aneurysm. Analyzing the results here as six distinct cohorts rather than four cohorts (as 
in the primary analysis) resulted in only minor diff erences due to diff erent weights given 
to sub-cohorts of the combined European cohort.
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 The most signifi cant association was detected in the previously reported 
[34] 9p21.3 region near CDKN2A and CDKN2B with P = 1.5 × 10-22 (OR = 1.32, 
PPA > 0.9999). All of the newly studied cohorts strongly supported this association 
with intracranial aneurysm (Figure 3). The same allele is associated with coronary 
artery disease but not with type 2 diabetes [121]. Similarly, the previously 
reported 8q11.23-q12.1 region showed signifi cant association. The 3′-SOX17 
interval (rs92986506) showed robust association with P = 1.3 × 10−12 (OR = 1.28, 
PPA > 0.9999) and all new cohorts supported the association of this SNP with 
intracranial aneurysm (Figure 3). For the 5′-SOX17 region (rs10958409), the new 
cohorts introduced a substantial heterogeneity, lowering the PPA to 0.016 (Figure 
3).
 Among the newly identifi ed loci, the strongest association was found at 
rs11661542 on 18q11.2 (OR = 1.22, P = 1.1 × 10-12, PPA > 0.9999). A cluster of SNPs 
that is associated with intracranial aneurysm spans the interval between 18.400 
Mb and 18.509 Mb and is strongly correlated with rs11661542 (Figure 2). A single 
gene, RBBP8 (encoding the retinoblastoma binding protein 8), is located within an 
extended linkage disequilibrium interval (Figure 2).
T he second strongest new association was at rs12413409 on 10q24.32 (OR = 1.29, 
P = 1.2 × 10-9, PPA = 0.9990), which maps to intron 1 of CNNM2 (encoding cyclin 
M2) (Fiurre 2). A cluster of SNPs that are strongly correlated with rs12413409 and 
are located within a ~247-kb interval in the same linkage disequilibrium block 
supported the association (Figure 2).
 The third new locus is defi ned by rs9315204 at 13q13.1 (OR = 1.20, 
P = 2.5 × 10-9, PPA = 0.9981) in intron 7 of STARD13 (encoding the StAR-related 
lipid transfer (START) domain containing 13) (Figure 2). Two SNPs, rs1980781 
and rs3742321, that are strongly correlated with rs9315204 (r2 > 0.9) also showed 
signifi cant association with intracranial aneurysm (Figure 2). These two SNPs 
are missense (lysine to arginine) and synonymous coding variants of STARD13, 
respectively. Another gene that has been implicated in aging phenotypes, KL 
(encoding klotho), is located nearby [122].
 A search of the gene-expression database (eQTL browser, see URLs) for all the 
intracranial aneurysm-risk loci did not reveal any consistent patt ern of association 
of intracranial aneurysm SNPs with variation in gene expression levels.
 In this second GWAS of intracranial aneurysm, which included nearly three 
times as many cases as the initial study, we detected three new risk loci and 
obtained strong independent evidence for association of two previously identifi ed 
loci. The evidence that these are bona fi de risk loci for intracranial aneurysm is 
very strong from both Bayesian measures and conventional P values.
 Given our power (~90%) to detect variants that confer risk of intracranial 
aneurysm with GRR = 1.25 and MAFs ≥ 10%, we expect that we have identifi ed 
most of these variants, limited principally by potential gaps in SNP coverage. 
Indeed, across the rest of the genome, there was no locus with PPA > 0.22 and 
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MAF ≥ 10%, whereas there were 14 loci with PPAs between 0.1 and 0.22 and ORs 
between 1.16 and 1.25 (data not shown). We expect that a fraction of these loci are 
genuine intracranial aneurysm risk loci, as suggested by the excess of SNPs with 
P < 1 × 10-3 (Figure 1b); exploring this possibility will require analysis of larger 
intracranial aneurysm cohorts and/or genotyping of alleles with lower MAFs.
 Based on the results of the fi rst GWAS of intracranial aneurysm and the 
role of the implicated gene products, Sox17 and p15INK4b-p16INK4a, we previously 
hypothesized [34] that the genes associated with intracranial aneurysm might 
play a role in determining cell cycle progression and may aff ect the proliferation 
[123] and senescence of progenitor-cell populations and/or the balance between 
production of progenitor cells versus cells committ ed to diff erentiation. Genes 
located within the newly identifi ed regions support this idea. The protein encoded 
by RBBP8, located within the 18q11.2 region, infl uences progression through the 
cell cycle by interacting with BRCA1 [124]. Similarly, of the two genes located 
within the 13q13.1 interval, STARD13 contains the Rho-GAP and C-terminal 
STAR-related lipid transfer (START) domains and its overexpression results 
in suppression of cell proliferation [125]. The other gene implicated here, KL, 
encodes a transmembrane protein that modulates FGF receptor specifi city [126]; 
mice lacking KL show accelerated aging in diverse organ systems [122].
 On the assumption that there is a fourfold increase in the risk of intracranial 
aneurysm among siblings of cases [127, 128] and that the SNPs combine to increase 
log-odds of disease in an additive fashion, the fi ve intracranial aneurysm risk loci 
explain 5.2% (within the Finnish cohort), 4.0% (in the European cohort) and 3.5% 
(in the combined JP1 and JP2 cohort) of the familial risk of intracranial aneurysm. 
Under this model, the odds of developing an intracranial aneurysm varies 4.99- 
to 7.63-fold across the top and bott om 1% of genetic risk profi les at these loci in 
the populations studied here and 3.61- to 4.64-fold across the 5% extremes. When 
combined with traditional risk factors such as gender, blood pressure and smoking, 
these fi ndings form the basis of future work aimed at preclinical identifi cation of 
individuals who are at high risk of intracranial aneurysm formation and rupture.
Methods
Genotyping
Whole-genome genotyping for the discovery cohort was performed on the 
Illumina platform according to the manufacturer’s protocol (Illumina). Replication 
genotyping in the JP1 cohort was performed using either Taqman (Applied 
Biosystems) or MassARRAY (Sequenom) assays. For the JP2 cohort, genotyping 
for cases was performed using the multiplex PCR-based Invader assay (Third 
Wave Technologies Inc.); genotyping for controls was performed on an Illumina 
platform as described previously [129].
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Ethics
The study protocol was approved by the Yale Human Investigation Committ ee 
(HIC protocol #7680). Institutional review board approval for genetic studies, along 
with writt en consent from all study participants, was obtained at all participating 
institutions.
Data storage and analysis tools
We used PLINK [130] v1.06 and R statistical environment v2.9.0 (in particular, the 
snpMatrix package [131]) for storage of genotype data and data analysis.
Preprocessing
Prior to the analysis of genotyping data, we excluded SNPs that were located 
either on mitochondrial DNA or sex chromosomes, SNPs with A/T or C/G alleles, 
those for which all subjects were assigned as ‘no call’, and those that were assayed 
on Hap300v1 or 550v1 but were dropped from newer versions.
Sample quality control
We excluded subjects in the discovery cohort who did not conform to our study 
design on the basis of genotyping and information quality, cryptic relatedness and 
population outliers. This fi ltering process resulted in the inclusion of 835 cases and 
6,529 controls in the Finnish cohort and 2,000 cases and 8,722 controls in the rest of 
the combined European cohort.
Imputation
We performed imputation analysis with the HapMap phase II CEU reference panel 
(release 24) using the IMPUTE v1 soft ware [115]. The analysis was performed 
separately for the Finnish and European cohorts. We converted posterior 
probabilities of three possible genotypes to fractional allele dosage scores (between 
0 and 2) and used these scores for association tests in order to take into account 
the imputation uncertainty [132]. For the quality assessment of imputed SNPs, we 
also converted the posterior probabilities to the most likely genotypes with the 
threshold at 0.9.
Case-control matching
Population stratifi cation and independent genotyping of cases and controls are 
major causes of confounding in GWAS [133]. Because our study consisted of 
multiple independently ascertained cohorts that were genotyped separately, we 
performed a stringent analysis to control for these biases by inferring the genetic 
ancestries of subjects [134, 135]. We used the Laplacian eigenmaps [136] to infer 
population structure. Following the determination of the number of dimensions 
(K + 1) using the threshold given in Lee et al. [137], we used the K-dimensional 
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nontrivial generalized eigenvectors [138] to calculate the Euclidean distance 
between any two subjects.
 In the course of this analysis, we excluded ‘isolated’ subjects who were 
identifi ed by using the nearest-neighbor distance distributions in any of the two-
dimensional sections. Aft er excluding these subjects, we observed 13 dimensions 
in the Finnish cohort and 5 dimensions in the European cohort. The larger 
dimensions observed in the Finnish sample could be att ributable to the presence 
of many isolated populations in Finland [113].
 Before matching, we stratifi ed data into males and females because female 
gender is a known risk factor of intracranial aneurysm [12, 112]. We also set the 
maximum distance between cases and controls to match to be less than 0.028 in the 
Finnish cohort and 0.009 in the European cohort. These values were determined 
by examining the distribution of the nearest-neighbor distances in K dimensions 
(data not shown). We matched cases and controls using the fullmatch function in 
the R-package optmatch [139, 140].
SNP quality control
For both genotyped and imputed SNPs in the discovery cohort, we applied quality-
control fi lters to individual cohorts and to cases and controls separately on the 
basis of the missing rate, MAF and the P value of the exact test of Hardy-Weinberg 
equilibrium [141]. For imputed SNPs, we also assessed imputation quality using 
the average posterior probability, MAF and allelic R2 metric [142]. Finally, we 
assessed diff erential missingness between cases and controls.
 Any genotyped SNP that passed the quality-control fi lters both in the 
European and Finnish cohorts was referred to as a ‘genotyped SNP’, and any one 
for which we used the quality control–passed imputation data either in one or 
both of the cohorts was classifi ed as an ‘imputed SNP’.
 For genotyping data of the replication cohorts, we excluded SNPs if any of 
the following three conditions were met in either cases or controls: (i) missing rate 
> 0.05; (ii) P value of the exact test of Hardy-Weinberg equilibrium < 0.001; or (iii) 
MAF < 0.01.
Statistical analysis
Cohort-wise association analysis 
We tested for association between each quality control-passed SNP and intracranial 
aneurysm using conditional and unconditional logistic regression for the discovery 
and replication cohorts, respectively [143]. For the discovery cohort, we used the 
matched strata to correct for potential confounding due to population stratifi cation 
and gender, and for the replication cohorts we adjusted for gender. We assumed 
the log-additive eff ect of allele dosage on disease risk. We obtained P values from 
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the score test (two-sided) and estimated the logarithm of per-allele ORs with 
standard errors by maximizing the conditional or unconditional likelihood. Both 
the test statistic and the standard error of the log of the OR were corrected using 
genomic control [116]. We performed the association analysis for the Finnish and 
European cohorts, as well as subcohorts of the European group that consisted of 
NL cases, DE cases or @neurIST cases and their matched controls (Table 1). We 
used the following R functions to perform the association analysis: clogit, glm and 
snp.rhs.tests [131].
Meta-analysis 
We combined the cohort-wise per-allele ORs in the Finnish and European cohorts 
using a fi xed-eff ects model of meta-analysis for 831,534 quality control–passed 
SNPs to obtain the discovery results. For SNPs analyzed both in the discovery and 
replication cohorts, we combined JP1 and JP2 to obtain replication results and all 
four cohorts to obtain combined results. Our primary analysis was based on the 
fi xed-eff ects model [132]. To assess the heterogeneity of the eff ect size between 
cohorts, we fi rst divided the European cohort into three groups as described 
above, aiming to analyze the data without averaging eff ect sizes over the combined 
European cohorts and then combined our six cohorts using the random-eff ects 
model. We employed the restricted maximum likelihood procedure to estimate 
the between-cohort heterogeneity variance (τ2) using the R function MiMa [144] 
(see URLs). From this estimate, we calculated the Cochran’s Q statistic and the 
I2 statistic (the percentage of variation across studies that is due to heterogeneity 
rather than chance) [145].
Bayesian evaluation of the strength of association 
To evaluate the strength of association with intracranial aneurysm, we used 
a Bayesian approach [118, 146]. A limitation of the use of P values alone is that 
variability in factors such as eff ect size, MAF and sample size can result in identical 
statistics that might correspond to markedly diff erent levels of evidence regarding 
the strength of association [119]. The Bayes factor provides an alternative that 
compares the probabilities of the data under the alternative hypothesis of association 
versus the null hypothesis of no association. For computational simplicity, we 
approximated the Bayes factor as described by Wakefi eld [117]. For all SNPs, we 
assumed the same prior distribution for the log-OR: a normal distribution with a 
mean of 0 and a standard deviation of log(1.5)/Φ−1(0.975), where Φ is the normal 
distribution function [118].
 The PPA [119] provides a simple probabilistic measure of evidence by 
introducing the prior probability of association, π1. We assumed a uniform prior, 
π1 = 1/10,000, for all the SNPs [120]. For Bayes factor > 106, changing π1 to a more 
conservative value of 1/100,000 would result in litt le change in the PPA.
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 To combine the results from multiple cohorts, we extended the formula [147] 
to be applicable to multiple (> 2) cohorts.
Conditional analysis 
For each region that contained a SNP with PPA > 0.5, we examined the number of 
independent association signals by testing for association of every genotyped SNP 
with intracranial aneurysm by adjusting for the eff ect of a specifi ed SNP.
Two-locus interaction analysis 
We tested for deviation from a linear model, which assumes that two SNPs combine 
to increase the log-odds of disease in an additive fashion, using conditional (in 
the Finnish and European cohorts) or unconditional (in JP1 plus JP2, stratifi ed by 
cohorts and gender) logistic regression. There was no signifi cant deviation from 
the linear model (data not shown).
Cumulative eff ect 
We evaluated potential clinical implications of the genetic profi les of the fi ve 
intracranial aneurysm risk loci following the approach described by Clayton [148]. 
We fi tt ed a fi ve-locus conditional (Finnish and European cohorts) or unconditional 
(Japanese cohorts) logistic regression model including the additive and 
dominance-deviation terms for each locus. Using the estimated eff ect sizes and 
each individual’s genotype, we calculated the risk scores for every individual. The 
receiver-operating characteristic curve for each ethnic cohort (Finnish, European 
and Japanese) was depicted using the risk score.
 We also calculated the ratio of the exponential of the mean of the risk scores 
for control subjects within the top versus bott om 5% or 1% tails of distribution of 
risk scores in each cohort to obtain approximated odds ratios of disease between 
these classes.
 The sibling recurrence risk was estimated by assuming the polygenic model 
that fi ts well to our data [148]. A fraction of the sibling recurrence risk att ributable 
to all of the fi ve loci was calculated by taking the ratio of the logarithm of this value 
and epidemiologically estimated value of 4 [127, 128].
URLs. eQTL browser, htt p://eqtl.uchicago.edu/.
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4.1 Prediction of 60-day case-fatality aft er aneurysmal 
subarachnoid haemorrhage
Background and Purpose: Aneurysmal subarachnoid haemorrhage (aSAH) is 
a devastating event with substantial case-fatality. Our purpose was to examine 
which clinical and neuro-imaging characteristics, available on admission, predict 
60-day case-fatality in aSAH and to evaluate performance of our prediction model.
Methods: We performed a secondary analysis of patients enrolled in the 
International Subarachnoid Aneurysm Trial (ISAT), a randomised multicentre trial 
to compare coiling with clipping in aSAH patients. Multivariable logistic regression 
analysis was used to develop a prognostic model to estimate the risk of dying 
within 60 days from aSAH based on clinical and neuro-imaging characteristics. 
The model was internally validated with bootstrapping techniques. 
Results: The study population comprised of 2,128 patients who had been 
randomised to either endovascular coiling or neurosurgical clipping. In this 
population 153 patients (7.2%) died within 60 days. World Federation of 
Neurosurgical Societies (WFNS) grade was the most important predictor of case-
fatality, followed by age, lumen size of the aneurysm and Fisher grade. The model 
discriminated reasonably between those who died within 60 days and those 
who survived (c statistic = 0.73), with minor optimism according to bootstrap re-
sampling (optimism corrected c statistic = 0.70).
Conclusion: Several strong predictors are available to predict 60 day case-fatality 
in aSAH patients who survived the early stage up till a treatment decision; aft er 
external validation these predictors could eventually be used in clinical decision 
making. 
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Introduction
Subarachnoid haemorrhage (SAH) is a devastating event, which is marked by 
sudden onset of severe headache, causing substantial case-fatality. In 85% of the 
patients, the SAH is caused by rupture of an aneurysm (aSAH) [1, 40]. From those 
who survive the fi rst month, approximately one third remains dependent with 
respect to daily activities during their remaining lifetime [40]. Amongst patients 
who regain independency, quality of life remains reduced [149]. 
 Early prediction of short term outcome in terms of case-fatality may 
support clinical decision making and may provide realistic and evidence based 
expectations to patients and relatives. Predictions may also be used to classify 
patients according to prognostic risk, which may be useful to compare outcome 
between diff erent patient series, to study treatment results over time, or to stratify 
patients for randomised clinical trials (RCT).
 Several other prognostic studies on outcome aft er aSAH have been performed, 
but most included relatively small numbers. Two included substantial numbers 
allowing analysis of the eff ects of multiple independent factors [150, 151]. However, 
these studies did not examine case-fatality, but arbitrarily dichotomized ordinal 
outcome scales (modifi ed Rankin Scale or Glasgow Outcome Scale). Moreover, 
due to their design, these studies were unable to examine the eff ect of treatment 
on prediction of outcome.
 Our aim was to develop a prognostic model for 60-day case-fatality, based on 
clinical features and neuro-imaging, regularly readily available on admission to 
a neurological or neurosurgical unit. These data were obtained from a large RCT 
conducted in mainly European countries. 
Methods 
Patients
Data were collected prospectively by the Medical Research Council funded 
International Subarachnoid Aneurysm Trial (ISAT) (International Standard 
Randomised Controlled Trial, number ISRCTN49866681). Full details of the ISAT 
study are available elsewhere [152]. The aim of the trial was to determine whether 
treatment using endovascular coiling reduced the risk of patients being dependent 
or dead at one year by 25 percent when compared with neurosurgical treatment 
(clipping). 
Predictors and outcome
We considered all patient characteristics that can be collected easily and reliably 
within the fi rst hours aft er hospital admission and that were also present in the 
ISAT database. These included age, gender, previous occurrence of SAH, CT scan 
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Fisher grading, lumbar puncture, World Federation of Neurosurgical Societies 
(WFNS) grading, number of intracranial aneurysms, location of the aneurysm, 
maximum lumen size of the aneurysm, vasospasm on angiography, and intended 
treatment by randomization. Fisher grading of blood visible on a plain CT 
scan runs from grade 1 (“no blood visible”) up to grade 4 (“intraventricular or 
intraparenchymal blood”). Lumbar puncture was not performed in all participants. 
If it was performed it was graded 1 (“no blood in cerebrospinal fl uid”) or 2 
(“xanthochromia or blood”); 0 otherwise (“no lumbar puncture”). WFNS scale 
runs from grade 1 (“Glasgow Coma Scale (GCS) 15 and no motor defi cit”) to 
grade 5 (“GCS 3-6 with or without motor defi cit”). One category additional to the 
standard WFNS scale was created in ISAT for those in whom WFNS could not 
be assessed; ‘grade 6’. The number of aneurysms was categorized in 1, 2, and 3 
or more intracranial aneurysms. We discerned four aneurysm locations: Anterior 
Cerebral Artery (ACA), Internal Carotid Artery (ICA), Middle Cerebral Artery 
(MCA), and Posterior Circulation (PC). The maximum lumen size of the aneurysm 
was expressed in millimetres. Vasospasm was examined on angiography and 
categorized as ‘none’, ‘mild’, ‘moderate’, or ‘severe’. Treatment was either 
neurosurgical clipping or endovascular coiling; we used treatment as allocated 
by the randomization procedure. We developed the model based on cases with a 
complete set of data. The outcome was 60-day case-fatality. 
Model 
We used univariate logistic regression analysis to estimate the association between 
single predictors and outcome, expressed as an odds ratio (OR). Predictors have 
a statistically signifi cant eff ect if the 95 percent confi dence interval (95% CI) does 
not include the value one. The prediction model was developed with multivariable 
logistic regression with backward stepwise selection. All potential predictors were 
entered into the model and those that met Akaike’s Information Criterion (AIC) 
were selected into the model. AIC compares models based on how well they fi t 
the data, but penalizes for the complexity of the model. AIC requires that the 
increase in model χ2 when entering a new predictor has to be larger than two 
times the degrees of freedom: χ2 > 2 df. When considering a predictor with 1 df, 
such as gender, this implies that χ2 has to exceed 2, equivalent to p < 0.157. When 
considering a predictor with 2 df, χ2 > 4, or p<0.135; and in case of 4 df, χ2 > 8, or 
p < 0.092 [153].
Performance 
The performance of the model was assessed with respect to calibration and 
discrimination. Calibration is the ability of the model to produce unbiased estimates 
of the probability of the outcome. Calibration was examined with a goodness of fi t 
test, which assesses agreement between predicted and observed risks over the full 
range of predicted probabilities [154].
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 Discrimination is the model’s ability to separate patients with diff erent 
outcomes. To quantify the discrimination, we used the concordance (c) statistic. For 
binary outcomes, c is identical to the area under the receiver operating characteristic 
curve [153]. The c statistic evaluates whether those with higher predicted risk are 
more likely to die within 60 days among all possible pairs of patients with diff erent 
outcomes. A model with a c statistic of 0.5 has no discriminative power at all, for 
example a coin fl ip. A c statistic of 1.0 refl ects perfect discrimination.
Model validation
The performance of a prediction model is generally worse in new patients 
than initially expected. This ‘optimism’ can be studied with internal validation 
techniques [153]. Internal validity of our model was assessed with standard 
bootstrapping procedures [153]. Bootstrapping involves drawing samples of 
patients with replacement from the study population. Each sample can be 
considered as if one is repeating the data collection with the same number of 
patients and under identical circumstances as the original. The multivariable 
logistic regression coeffi  cients were re-estimated in 300 bootstrap samples. Each 
of these 300 models was evaluated on the original sample. The average diff erence 
in the c statistic was determined to indicate the optimism in the initially estimated 
discriminative ability [153]. A shrinkage factor was estimated from the bootstrap 
validation procedure and we shrunk the regression coeffi  cients to provide bett er 
predictions for future patients [153]. 
 All statistical analyses were performed using R soft ware, version 2.8.1 (R 
Foundation for Statistical Computing, Vienna, Austria).
Results
A total of 2,143 patients were recruited into the ISAT trial by 43 neurosurgical 
centres, mainly in Europe. CT scans of 14 patients were not performed or available, 
and in one patient no information on vasospasm was available. We excluded these 
cases from our analysis. Data on the outcome were available for all patients. Thus, 
we performed complete case analysis on 2,128 patients (99.3%) of whom 153 (7.2%) 
died within 60 days.
 The distribution of patient characteristics of the study population is presented 
in Table 1. For reasons of small numbers in the ‘severe’ category of vasospasm, 
we aggregated data from the ‘moderate’ and ‘severe’ categories into one category. 
Univariate analysis showed a statistically signifi cant relation with 60-day case-
fatality for age, lumen size, Fisher grade, lumbar puncture, WFNS grade, and 
vasospasm. Sex, location and number of aneurysms and intended treatment were 
not signifi cantly associated with 60-day case-fatality (Table 1). In the multivariable 
model with stepwise backward selection age, lumen size, Fisher grade, and WFNS 
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grade met AIC and were included in the fi nal model. In Table 2 the chi square 
statistics with corresponding p-values are presented as well as the point estimate 
of the OR. Age and WFNS grade were the most important predictors.
Table 1. Population characteristics and univariate association with 60-day case fatality.
Predictor alive n=1975 death n=153
median IQR median IQR beta SE OR CImin CImax
age [10years] 5.2 4.3-5.9 5.6 5.0-6.5 0.36 0.08 1.43 1.23 1.66
lumensize [mm] 5 4-7 6 4-8 0.10 0.02 1.10 1.05 1.15
n % n %
Sex
female 1236 63 103 67 1
male 739 37 50 33 -0.21 0.18 0.81 0.57 1.15
previous SAH
yes 129 7 6 4 -0.54 0.43 0.58 0.25 1.35
no 1846 93 147 96 1
Fisher grade
1 112 6 2 1 1
2 350 18 10 7 0.47 0.78 1.60 0.35 7.41
3 840 43 62 41 1.42 0.73 4.13 1.00 17.13
4 673 34 79 52 1.88 0.72 6.57 1.59 27.13
Lumbar puncture 
xantochromia or 
blood 217 11 7 5 -0.95 0.39 0.39 0.18 0.84
no blood 5 0 0 0 -5.19 20.8 0.01 0.00 ∞
no puncture 1753 89 146 95 1
WFNS grade
1 1270 64 54 35 1
2 495 25 51 33 0.89 0.20 2.42 1.63 3.60
3 120 6 13 8 0.94 0.32 2.55 1.35 4.80
4 55 3 19 12 2.09 0.30 8.12 4.51 14.63
5 13 1 7 5 2.54 0.49 12.66 4.86 33.02
6 (not assessable) 22 1 9 6 2.26 0.42 9.62 4.23 21.89
n of aneurysms detected
1 1555 79 116 76 1
2 314 16 29 19 0.21 0.22 1.24 0.81 1.89
>=3 106 5 8 5 0.10 0.38 1.10 0.52 2.32
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Predictor alive n=1975 death n=153
median IQR median IQR beta SE OR CImin CImax
Location
ACA 1008 51 71 46 -0.16 0.19 0.85 0.59 1.23
ICA 638 32 53 35 1
MCA 277 14 23 15 0.00 0.26 1.00 0.60 1.66
PC 52 3 6 4 0.33 0.45 1.39 0.57 3.38
vasospasm 
none 1575 80 109 71 1
mild 218 11 24 16 0.46 0.24 1.59 1.00 2.53
moderate/severe 182 9 20 13 0.77 0.26 2.15 1.30 3.55
intended treatment
clip 983 50 83 54 1
coil 992 50 70 46 -0.18 0.17 0.84 0.60 1.16
 IQR = inter quartile range; beta = regression coeffi  cient in the logistic regression model; SE = standard 
error; OR = odds ratio; CImin = lower limit of the 95% confi dence interval; CImax = upper limit of the 95% 
confi dence interval.
Table 2. Statistical parameters of the fi nal model.
factor X2 df p-value OR 95% CIa
WFNS grade 51 5 8 × 10-10 grade 1 = ref.
2 1.87 1.23-2.83
3 1.70 0.87-3.32
4 4.87 2.60-9.14
5 7.00 2.54-19.28
6 5.75 2.41-13.73
age [10 yrs] 17 1 4 × 10-5 1.32 1.13-1.55
lumen size [mm] 12 1 4 × 10-4 1.08 1.03-1.13
Fisher grade 8 3 0.04 grade 1 = ref.
2 1.43 0.27-7.65
3 2.67 0.53-13.51
4 2.76 0.54-14.14
X2 is the chi squared test statistic for the predictor in the fi nal model; df = degrees of freedom; a 95% 
CI was calculated based on the S.E. of the estimates of the coeffi  cients in the full model to avoid 
underestimation of uncertainty.
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 The goodness of fi t test yielded a p-value of 0.86, suggesting that the model 
fi tt ed the data in which it was developed well. The c statistic of the original model 
was 0.73, meaning that the model discriminates reasonably between patients who 
die within 60 days from onset of the SAH and those who survive this period.
 Validation by means of 300 bootstrap samples resulted in a shrinkage factor 
of 0.85, which was applied to the betas of the model. The c statistic of the internally 
validated model was 0.70. Details of the fi nal prognostic model for 60-day case-
fatality are described in the appendix. 
Discussion
We developed a prognostic model to predict the risk of 60 day case-fatality in 
individual patients aft er aSAH. Predictions were based on characteristics that are 
regularly readily available on admission to a neurological or neurosurgical unit 
and which were collected in a large clinical trial. The full model yielded a c statistic 
of 0.73. 
 Previously, several models to estimate the probability of unfavourable 
outcome aft er aSAH have been developed. Our model was similar to those; we 
included roughly the same predictors: age, clinical status, and lumen size [150, 
151, 155]. However, our study is of added value because of the substantial size and 
the inclusion of both clipped and coiled patients. The studies by Hoh et al. [150] 
(n = 515) and Mocco et al. [155] (n = 148) contained relatively few patients. The 
small numbers of coiled patients (79 and 35, respectively) and the design of the 
study did not allow for taking the eff ect of treatment in consideration. The study 
of Rosengart et al. [151] (n = 3667) was not able to do that either, since patients 
treated with Guglielmi or other detachable coils were excluded. All three studies 
used a dichotomized ordinal scale as an outcome, for which the cut off  can be 
(arbitrarily) chosen in diff erent studies. In a sense, examining case-fatality is also 
a dichotomization of an ordinal scale, though less arbitrary. Therefore, we are 
convinced that logistic regression is well suited for an outcome that is by its nature 
dichotomous, whereas for an ordinal outcome we would prefer specifi c modelling 
techniques.
 Several limitations of this study should be acknowledged. This study used 
data from one large trial on a selected population of patients who survived the 
early stage up till a treatment decision and who were in equipoise regarding that 
decision on treatment with either endovascular coiling or neurosurgical clipping, 
which may limit external validity. The model may perform well in this development 
sample, but worse when applied to other groups of patients, for example, a less 
strictly selected population. Nonetheless, according to a recently published paper, 
the ISAT population proved to be quite similar to the population admitt ed with 
an aSAH to neurosurgical units in the United Kingdom [156]. Although in ISAT, a 
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lower proportion of poor grade patients were enrolled. Validation of a prognostic 
model in independent patient series is therefore considered an essential next step 
[157]. However, since large samples of systematically collected data on aSAH are 
sparse, assessment of external validity is diffi  cult. For now the external validity of 
our model remains to be established. This will be a topic of future research. 
 Although our model represents knowledge obtained from 2,128 SAH patients 
in equipoise regarding treatment, statistical models can never replace the clinician 
with regard to decision making; they can only assist with this task. A prediction for 
an individual aSAH patient a particular situation is always subject to uncertainty. 
The model makes certain structural assumptions and statistical interaction terms 
were not included. It is hence possible that specifi c patt erns of risk factors are 
inadequately refl ected in the model predictions. Therefore, predictions should be 
regarded with care and not directly be applied for treatment limiting decisions. 
 Although the performance of the presented model was satisfactory, it might 
potentially be improved by including neuro-imaging biomarkers other than lumen 
size, location, Fisher grade on plain CT scan, and vasospasm on angiography. 
Biomarkers regarding anatomy and morphology might be considered, as well as 
aneurysm characteristics obtained from three and four dimensional angiography 
[158, 159]. Performance may also be improved by inclusion of subsequent 
information obtained aft er admission, including temporal course, neuro-imaging 
at later time points, eventual rebleeding of the aneurysm, delayed ischemic defi cit, 
and other parameters such as hydrocephalus. The objective of the present study, 
however, was to investigate prognostic models that predict 60-day case-fatality 
with predictors available on admission.
 Statistical testing for calibration has a number of drawbacks. First, the null 
hypothesis is of good calibration. Hence, if we test calibration in a small study, we 
have low power and will not reject the null hypothesis unless miscalibration is 
very severe. On the other hand, even a model with very good, though not perfect, 
calibration will fail the test in case of a suffi  ciently large sample. Moreover, reported 
goodness-of-fi t tests are usually non-signifi cant if they refl ect apparent validation 
on the data that were also used to construct the model. Such non-signifi cant results 
may contribute to the face validity of a model, but have no real scientifi c meaning 
[153].
In conclusion, we presented a prognostic model for predicting 60-day case-fatality 
aft er aneurysmal SAH. Our model contained age, lumen size, Fisher grade, and 
WFNS grade as predictors. Aft er calibration and internal validation, our model 
showed reasonable performance, although external validity of our model remains 
to be established.
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Appendix
Details of the Prognostic Model
The probability of dying within 60 days is calculated according to the logistic 
formula: 1/(1 + exp-LP). The linear predictor (LP) takes the form of LP = intercept 
+ regression coeffi  cients × predictor values. LP for 60-day case-fatality = -5.812 + 
0.2762 × age + 0.3572 × [Fisher grade II] + 0.9756 × [Fisher grade III] + 1.008 × [Fisher 
grade IV] + 0.6216 × [WFNS grade 2] + 0.5261 × [WFNS grade 3] + 1.574 × [WFNS 
grade 4] + 1.934 × [WFNS grade 5] + 1.738 × [WFNS grade not assessable] + 0.07662 
× lumen size of aneurysm.
 Coding of the predictors was as follows: age in decades, lumen size in 
millimetres; all other predictors, 1 if true and 0 if false.
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4.2 Prediction of two month modifi ed Rankin Scale with 
an ordinal prediction model in patients with aneurysmal 
subarachnoid haemorrhage
Background and Purpose: Aneurysmal subarachnoid haemorrhage (aSAH) is a 
devastating event with a frequently disabling outcome. Our aim was to develop a 
prognostic model to predict an ordinal clinical outcome at two months in patients 
with aSAH. 
Methods: We studied patients enrolled in the International Subarachnoid 
Aneurysm Trial (ISAT), a randomized multicentre trial to compare coiling and 
clipping in aSAH patients. 
Several models were explored to estimate a patient’s outcome according to the 
modifi ed Rankin Scale (mRS) at two months aft er aSAH. Our fi nal model was 
validated internally with bootstrapping techniques.
Results: The study population comprised of 2,128 patients of whom 159 patients 
died within 2 months (7.5%). Multivariable proportional odds analysis identifi ed 
World Federation of Neurosurgical Societies (WFNS) grade as the most important 
predictor, followed by age, sex, lumen size of the aneurysm, Fisher grade, 
vasospasm on angiography, and treatment modality. The model discriminated 
moderately between those with poor and good mRS scores (c statistic = 0.65), with 
minor optimism according to bootstrap re-sampling (optimism corrected c statistic 
= 0.64).
Conclusion: We presented a calibrated and internally validated ordinal prognostic 
model to predict two month mRS in aSAH patients who survived the early stage 
up till a treatment decision. Aft er external validation this model could eventually 
be used to support clinical decision making.
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Introduction
Prediction research typically aims to predict outcome of individual patients aft er 
the onset of a certain disease, using prognostic models. These models, preferably 
based on data directly available at hospital admission, are essential to support 
clinical decision making, and to facilitate reliable comparison of outcomes 
between diff erent patient series and variation in results over time. Furthermore, 
prognostic models have an important role in randomized controlled trials (RCT), 
for stratifi cation [160] and statistical analyses that explicitly consider prognostic 
information, such as covariate adjustment [161, 162], and may provide realistic 
and evidence-based expectations to relatives.
 The majority of published prognostic models predict a binary outcome, 
such as case-fatality using binary logistic regression [163-166]. Also, outcomes at 
ordinal scales are oft en considered as a dichotomized variable. However, there 
are several objections against collapsing an ordinal outcome scale into a binary 
one. First, the cut off  for dichotomisation is arbitrary and may vary over studies 
in a single medical fi eld [163, 164, 166]. Secondly, from a statistical perspective 
dichotomisation is a waste of information and reduces statistical power for the 
analysis of treatment eff ects or other covariates of interest [167, 168]. Furthermore, 
from a clinical point of view dichotomisation may lead to less useful models. For 
example, for a patient with a minor stroke a model predicting survival versus 
mortality is of limited value since the risk is low, while a prediction of complete 
recovery versus some remaining symptoms may be very useful. For a patient with 
a severe stroke, this will be the other way around.
 An alternative for dichotomisation is application of a statistical approach 
that uses the full ordinal outcome scale. This leads to effi  cient use of the data and 
clinically relevant predictions. Several of these approaches for modelling ordinal 
response variables have been proposed, including proportional odds (PO) logistic 
regression, multinomial (or polytomous) logistic regression, or simple linear 
regression [153]. Each of these methods has its pros and cons. 
 Our aim was to develop an ordinal prognostic model to predict clinical 
outcome at two months in patients with aneurysmal subarachnoid haemorrhage 
(aSAH), based on clinical features and neuro-imaging which are regularly 
readily available on admission to a neurological or neurosurgical unit. SAH is a 
devastating event, causing substantial mortality. In 85% of the patients, the SAH 
is caused by rupture of an aneurysm (aSAH) [1, 40]. Of those who survive the 
fi rst month, approximately one third remains dependent with respect to daily 
activities during the remaining lifetime [40]. Also amongst patients who regain 
independency, quality of life remains reduced [149]. A frequently used outcome 
measurement is the modifi ed Rankin Scale (mRS) [169]. This is an ordered scale for 
measuring motor function and runs from 0 (no symptoms at all) to 6 (dead) (Table 
1). 
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Table 1. Defi nition of the modifi ed Rankin scale.
Grade Description
0 No symptoms at all
1 No signifi cant disability despite symptoms; able to carry out all usual duties and 
activities
2 Slight disability; unable to carry out all previous activities, but able to look aft er own 
aff airs without assistance
3 Moderate disability; requiring some help, but able to walk without assistance
4 Moderately severe disability; unable to walk without assistance and unable to att end 
to own bodily needs without assistance
5 Severe disability; bedridden, incontinent and requiring constant nursing care and 
att ention
6 Dead
Material and methods 
Patients
Data were collected prospectively by the Medical Research Council funded 
International Subarachnoid Aneurysm Trial (ISAT) (International Standard 
Randomised Controlled Trial, Number ISRCTN49866681). Full details of ISAT are 
available elsewhere [152]. The aim of the trial was to determine whether treatment 
using endovascular coiling reduced the risk of patients being dependent or dead 
at one year by 25 percent (as defi ned by modifi ed Rankin Scale grade 3-6) when 
compared with neurosurgical treatment (clipping) for that cohort of patients. 
Predictors and outcome
We considered all patient characteristics that could be obtained easily and reliably 
within the fi rst hours aft er hospital admission and that were also present in the ISAT 
database. These included age, gender, previous occurrence of SAH, CT scan Fisher 
grading, World Federation of Neurosurgical Societies (WFNS) grading, number 
of intracranial aneurysms, location of the aneurysm, maximum lumen size of the 
aneurysm, vasospasm on angiography, and intended treatment at randomization. 
Fisher grading of blood visible on a plain CT scan runs from grade 1 (“no blood 
visible”) up to grade 4 (“intraventricular or intraparenchymal blood”). WFNS scale 
runs from grade 1 (“Glasgow Coma Scale (GCS) 15 and no motor defi cit”) to grade 
5 (“GCS 3-6 with or without motor defi cit”). One additional grade was created in 
ISAT for those in whom WFNS could not be assessed; ‘grade 6’. The number of 
aneurysms was dichotomized into one or more than one intracranial aneurysms. 
Four aneurysm locations were distinguished: Anterior Cerebral Artery (ACA), 
Internal Carotid Artery (ICA), Middle Cerebral Artery (MCA), and Posterior 
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Circulation (PC). The maximum lumen size of the aneurysm was expressed in 
millimetres. Vasospasm was examined on angiography and dichotomized into 
‘absent’ or ‘present’. Treatment was either neurosurgical clipping or endovascular 
coiling; we used treatment as allocated by the randomization procedure. The 
outcome measure in our study was the modifi ed Rankin Scale (mRS) at two 
months (Table 1) [169]. 
Model 
We started the development of the model discarding patients without information 
on outcome. The few missing values in predictors were imputed by means of 
single imputation (SI, in R language: aregImpute, n.impute=1, type=’pmm’). 
 A simple approach to analyze an ordinal outcome, such as the mRS, is to 
dichotomize the outcome variable by one of several possible cut off  points, e.g. 01 
vs. 23456 [164], 012 vs. 3456 [152, 163], 0123 vs. 456 [166], and 012345 vs. 6 (case-
fatality) [165]. We applied binary logistic regression to develop models for these 
dichotomized responses. Next, we addressed the two main aspects of our ordinal 
outcome; the fact that it contains order and separate categories. A simple solution 
for modelling order, while neglecting the categorised nature of our outcome, 
is to apply linear regression using ordinary least squares. For the opposite – 
modelling categories, while neglecting order – we used multinomial regression. 
A more sophisticated approach is to use a proportional odds (PO) model. Such 
a model takes both order and separate categories into account. The PO logistic 
model is a rather straightforward extension of binary logistic regression [170]. A 
common set of regression coeffi  cients is assumed across all levels of the outcome, 
and intercepts are estimated for each level. The advantage of the PO model is its 
parsimony in dealing with an ordered outcome. The price we pay is the assumption 
of proportionality of the odds. This assumption is equivalent to saying that any 
cut-point on the outcome scale would lead to the same (binary) logistic regression 
coeffi  cient [153].
 We inspected proportionality by studying the univariate odds ratios for each 
cut off  for each predictor. We plott ed the score residuals of binary logistic models 
for each potential predictor separately. The trend of the score components against 
the levels of the outcome scale should be fl at if the proportional odds assumption 
holds [171]. When the PO assumption is not fulfi lled for all potential predictors, 
we could also investigate a further alternative model: the partial PO model [172].
 The association between predictors and outcome is expressed as odds ratios 
(OR). Predictors have statistically signifi cant eff ects when the 95% confi dence 
interval does not include the value one. 
 A multivariable PO model was developed containing predictors that met 
Akaike’s Information Criterion (AIC) in a backward stepwise procedure [173]. 
AIC compares models based on how well they fi t the data, but penalizes for the 
complexity of the model. AIC requires that the increase in model χ2 when entering 
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a new predictor has to be larger than two times the degrees of freedom: χ2 > 2 df. 
When considering a predictor with 1 df, such as gender, this implies that χ2 has to 
exceed 2, equivalent to p < 0.157. When considering a predictor with 2 df, χ2 > 4, or 
p < 0.135; and in case of 4 df, χ2 > 8, or p<0.092 [153]. 
Performance 
The performance of the fi nal PO model was assessed with respect to calibration 
and discrimination. Calibration is the ability of the model to produce unbiased 
estimates of the probability of the outcome. Calibration was tested with a goodness 
of fi t test, which assesses agreement between predicted and observed risks over 
the full range of predicted probabilities. Discrimination is the model’s ability to 
separate patients with diff erent outcomes. To quantify the discrimination, we used 
the c statistic. A model with a c statistic of 0.5 has no discriminative power at all, 
for example a coin fl ip. A c statistic of 1.0 refl ects perfect discrimination.
Model validation
The performance of a prediction model is generally worse in new patients then 
initially expected. This ‘optimism’ of the original model can be studied with 
internal validation techniques [153]. Internal validity of the models was assessed 
with standard bootstrapping procedures. Bootstrapping involves drawing samples 
of patients with replacement from the development population. Each sample can 
be considered as if one is repeating the data collection with the same number of 
patients and under identical circumstances as the original. Regression models 
were estimated in 300 bootstrap samples. Each of these 300 models was evaluated 
on the original sample. The average diff erence in the c statistic was determined 
to indicate the optimism in the initially estimated discriminative ability [153]. A 
shrinkage factor was estimated from the bootstrap validation procedure and we 
shrunk the regression coeffi  cients to provide bett er predictions for future patients 
[153]. 
 All statistical analyses were performed using R soft ware, version 2.8.1 (R 
Foundation for Statistical Computing, Vienna, Austria). 
 
Results
A total of 2,143 patients were recruited to the ISAT trial by 43 neurosurgical centres, 
mainly in Europe. We excluded 15 patients with missing information on the two 
month mRS. Fisher grade of 14 patients was not available and in one patient no 
information on vasospasm was available. We statistically imputed these missing 
values, leaving 2,128 patients for analysis, of whom 347 were in mRS grade 0 (16%), 
583 in mRS grade 1 (27%), 528 in mRS grade 2 (25 %), 296 in mRS grade 3 (14 %), 80 
in mRS grade 4 (4 %), 135 in mRS grade 5 (6%) at the two month assessment, and 
of whom 159 (8 %) died before the two month assessment. 
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Table 2. Univariate associations for diff erent cut off s for mRS (odds ratios), the univariate 
PO estimate (odds ratios), and linear regression (linear regression coeffi  cient).
1 2 3 5 PO linear
age [10years] 1.19 1.38 1.48 1.49 1.26 1.28
lumensize [mm] 1.05 1.06 1.08 1.10 1.05 1.06
Sex
Male 0.67 0.71 0.83 0.86 0.69 0.75
previous SAH
Yes 1.19 1.01 0.61 0.55 1.04 0.93
Fisher grade
1 1 1 1 1 1 1
2 0.93 1.39 2.29 2.01 0.99 1.09
3 1.29 2.51 4.45 4.32 1.50 1.67
4 2.03 4.47 7.72 7.31 2.49 2.72
WFNS grade
1 1 1 1 1 1 1
2 1.94 2.47 2.60 2.40 2.08 1.99
3 3.34 4.46 3.67 2.64 3.51 3.18
4 6.74 7.85 12.55 7.84 8.38 7.99
5 6.06 10.83 16.26 12.00 12.43 11.25
(not assessable) 6 5.35 9.92 13.14 9.55 9.97 9.37
number of IA
>1 1.11 1.21 1.30 1.17 1.15 1.15
location
ICA 1 1 1 1 1 1
ACA 0.86 0.83 1.04 0.90 0.86 0.90
MCA 0.80 0.95 1.01 0.97 0.84 0.88
PC 0.89 0.83 1.74 1.39 0.97 1.06
vasospasm
present 1.69 1.65 1.49 1.71 1.67 1.60
intended treatment
Coil 0.69 0.60 0.81 0.88 0.68 0.73
 Univariate analyses in the binary models for diff erent cut off s, the PO model, 
and the linear regression model are presented in Table 2. The ORs for each cut off  
were reasonably similar except for previous SAH (fu_prevhaem) and Fisher grade 
2 (Fisher=2). This violation of the PO assumption is also noted by statistically 
signifi cant deviations from the horizontal line in Figure 1. The linear regression 
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coeffi  cients were surprisingly close to the ORs from the PO model. The multinomial 
model yielded 108 coeffi  cients, apart from 6 intercepts (not shown). In a partial PO 
model 6 intercepts were fi tt ed, 6 coeffi  cients for previous SAH, 18 coeffi  cients for 
Fisher grade, and one for each of the other predictors (not shown). 
 For the sake of interpretability and clinical usefulness, we chose to accept 
the violation of the PO assumption in the PO model. Age and WFNS grade were 
the most important predictors in the multivariable PO model (Table 3). Other 
statistically signifi cant predictors were sex, lumen size, Fisher grade, vasospasm, 
and treatment modality. 
 The goodness of fi t test yielded a p-value smaller then 0.05 for all levels of 
mRS, suggesting that the model poorly fi tt ed the data in which it was developed. 
In our fi nal model the PO assumption was violated only for Fisher grade 2 (Figure 
2). The c statistic of the fi nal model was 0.65 (optimism-corrected: 0.64). Details of 
the model are described in the appendix. 
Table 3. Final PO and linear models – shrunken estimates of OR and regression coeffi  cients.
PO Linear
OR CImina CImaxa coeffi  cient CImina CImaxa
age [10years] 1.18 1.10 1.26 1.20 1.13 1.27
lumensize [mm] 1.04 1.01 1.07 1.04 1.02 1.07
Sex
Male 0.78 0.66 0.91 0.85 0.73 0.98
Fisher grade
1 1 1
2 1.00 0.69 1.43 1.07 0.77 1.49
3 1.28 0.91 1.79 1.37 1.01 1.86
4 1.50 1.06 2.13 1.56 1.13 2.14
WFNS grade
1 1 1
2 1.74 1.44 2.10 1.68 1.42 1.98
3 2.43 1.75 3.39 2.27 1.69 3.04
4 6.04 3.90 9.37 5.70 3.89 8.35
5 7.90 3.43 18.17 7.56 3.72 15.35
(not assessable) 6 7.70 3.91 15.16 7.00 3.92 12.50
vasospasm 
present 1.36 1.13 1.64 1.30 1.10 1.54
intended treatment
Coil 0.69 0.60 0.81 0.75 0.65 0.85
OR = odds ratio; CImin = lower limit of the 95% confi dence interval; CImax = upper limit of the 
95% confi dence interval. a 95% CI was calculated based on the standard error of the estimates of the 
coeffi  cients in the full model to avoid underestimation of uncertainty.
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Figure 1. Residual plots (score.binary) of univariate associations of potential predictors to 
examine deviations from the PO assumption.
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Figure 2. Residual plots (score.binary) of predictors in the selected multivariable model 
to examine deviations from the PO assumption.
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Discussion
We developed and validated a prognostic proportional odds model to predict the 
risk of two month modifi ed Rankin Scale in individual patients aft er aneurysmal 
subarachnoid haemorrhage. Predictions were based on characteristics that were 
collected in a large clinical trial and that are regularly readily available on admission 
to a neurological or neurosurgical unit. The c statistic was modest, indicating a 
mediocre ability to predict clinical outcome at the two month assessment. 
 The dependence of our proportional odds model on the assumption of 
proportionality should not be overstressed. The potential inaccuracy caused by 
mild violation of the PO assumption is likely less severe than would be the case 
in arbitrary dichotomisation of an ordinal outcome. Dichotomisation involves 
more loss of information [174]. Probably one would prefer a “wrong, but useful” 
model, despite possibly violating some underlying model assumptions [175]. 
Moreover, the PO model predicts the probability of being in each mRS level for 
each individual patient. This makes the model useful for all patients, regardless of 
severity.
 Besides the PO model we explored several other models. The ordinary 
least squares model seemed to perform quite well (see Table 3). Although the 
categorical nature of the outcome variable is neglected, the model seems to perform 
reasonable and may yield estimates of regression coeffi  cients that are quite similar 
to the PO model. This model might suffi  ce to gain insight in which predictors 
play an important role in this clinical question. On the contrary, the multinomial 
model and – to a lesser extent – the partial PO models suff er from highly limited 
interpretability and therefore usability. A plethora of coeffi  cients is produced by 
these models. If one is very specifi cally interested in one outcome grade, the model 
might be of some use. In most cases, we consider a more pragmatic approach 
however preferable. There are many more potentially useful modelling techniques 
for ordinal outcomes [176, 177]. One such technique is the continuation ratio (CR) 
model, which has been said to be likely to fi t ordinal responses when subjects 
have to ‘pass through’ one category to get to the next. For a worked example see a 
tutorial by Harrell et al. [171]. 
 Several limitations of our analyses should be acknowledged. This study 
used data from one large trial on a selected population of patients in equipoise 
regarding treatment with either endovascular coiling or neurosurgical clipping, 
which limits generalizability. Nonetheless, according to a recently published 
paper, the ISAT population proved to be quite similar to the population admitt ed 
with an aSAH to neurosurgical units in the United Kingdom [156]. The model 
may perform well in the development sample, but poorly when applied to 
other groups of patients, for example, a less strictly selected one. Validation of 
a prognostic model in independent patient series is considered an essential next 
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step [157]. However since large samples of systematically collected data on aSAH 
are sparse, assessment of external validity is diffi  cult. For now the generalizability 
and overall validity of our model remains to be established. This will be a topic of 
future research.
 Although our model represents knowledge obtained from 2,128 SAH patients, 
predictions for individual aSAH patients are always subject to uncertainty. The 
model makes certain structural assumptions and statistical interaction terms 
were not included. Hence, it is possible that specifi c patt erns of risk factors are 
inadequately refl ected in the model predictions. Therefore, predictions should be 
regarded with care and not directly be applied for treatment limiting decisions. 
 The modest performance of the presented model might potentially be 
improved by including neuro-imaging biomarkers other than lumen size, location, 
Fisher grade on plain CT scan, and vasospasm on angiography. Biomarkers 
regarding anatomy and morphology might be considered, as well as aneurysm 
characteristics obtained from three and four dimensional angiography [158, 
159]. Performance may also be improved by inclusion of subsequent information 
obtained aft er admission, including temporal course, neuro-imaging at later time 
points, eventual rebleeding of the aneurysm, delayed ischemic defi cit, and other 
parameters such as hydrocephalus. The objective of the present study, however, 
was to investigate prognostic models that predict two month mRS with predictors 
available at admission.
In conclusion, we presented a calibrated and internally validated ordinal prognostic 
model for predicting two month outcome aft er aSAH. Aft er external validation 
this model could eventually be used to support clinical decision making.
Appendix
Details of the Prognostic Model
The probability of an outcome (mRS level) within two months is calculated 
according to the logistic formula: 1/(1 + exp-LP). The linear predictor (LP) takes 
the form of LP = intercept + regression coeffi  cients × predictor values. LP for 
mRS = 0.250 [mRS ≥ 1] – 1.15 [mRS ≥ 2] – 2.25 [mRS ≥ 3] – 3.08 [mRS ≥ 4] – 3.39 
[mRS ≥ 5] – 4.11 [mRS≥6] + 0.164 × age – 0.255 × [male] – 0.00445 × [Fisher grade 
II] + 0.245 × [Fisher grade III] + 0.404 × [Fisher grade IV] + 0.555 × [WFNS grade 2] 
+ 0.889 × [WFNS grade 3] + 1.80 × [WFNS grade 4] + 2.07 × [WFNS grade 5] + 2.04 
× [WFNS grade 6, ‘not assessable’] + 0.0404 × lumen size of aneurysm + 0.307 × 
[vasospasm present]– 0.367 [coil].
Coding of the predictors was as follows: age in decades, lumen size in 
millimetres; all other predictors, 1 if true and 0 if false.

Chapter 5
General discussion
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The aim of the studies described in this thesis was to examine certain epidemio-
logical aspects of occurrence, aetiology, and predictors for outcome of subarachnoid 
haemorrhage (SAH). The studies were performed in the context of the @neurIST 
project, a European Commission funded project focusing on integration of know-
ledge on intracranial aneurysms from molecular level up to population level. One 
of the overall aims of the project was to develop an individualised prediction 
model that would allow predicting behaviour of an unruptured aneurysm and 
outcome of eventual rupture of an aneurysm. To reach this fi nal aim, several 
intermediate questions have to be solved. This additional information was 
necessary to complement data from literature in populating a decision tree that 
would allow for prediction of risk in patients with an intracranial aneurysm. To 
that extent it was necessary to obtain frequency and association measures in as 
many subgroups (gender, age, main risk factors) as possible since these data are 
oft en missing in the literature.
 In this chapter, I will fi rst summarize the main fi ndings of our studies. 
Secondly, I will discuss several general methodological issues related to the 
studies described in this thesis. Finally, some directions for future research will be 
suggested. 
Main fi ndings
Incidence of subarachnoid haemorrhage
We investigated the incidence of aneurysmal SAH in the general Dutch 
population (chapter 2). We conducted our study in two diff erent databases; the 
Dutch nationwide hospital registry (Landelĳ ke Medische Registratie, LMR) and 
the Integrated Primary Care Information (IPCI) database. The overall incidence 
rate of SAH observed in the LMR database was 7.12 per 100,000 person years 
(95% CI: 6.94-7.31); those found in IPCI 5.53 (95% CI: 4.56-6.66). These fi ndings 
represent between 800 and 1200 new cases of SAH each year in the Netherlands. 
The incidence increased with age from around 1.30 (95% CI: 0.75-2.06) in the age 
category under 40 years up to 18.05 (95% CI: 16.51-19.69) (LMR) in persons over 80 
years of age. Preponderance was observed in the incidence rates in females. The 
overall incidence rate ratio of SAH for women compared to men was 1.72 (95% 
CI: 1.63-1.81). This diff erential risk occurred gradually and was most pronounced 
in the fourth and fi ft h decade, appearing from the fourth decade of life onwards. 
Risk of subarachnoid haemorrhage due to statins, antithrombotics, 
and oral contraceptives
Since most risk factors for (aneurysmal) SAH are similar to risk factors for 
cardiovascular disease, we were interested to investigate whether drugs that 
may actually impact on cardiovascular disease, through their action on vascular 
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endothelium, may be associated with SAH. Vascular endothelium, which is 
aff ected by statins, is believed to play a role in SAH [55]. Although statins decrease 
cerebrovascular event rates during use, withdrawal of statins causes a rebound 
eff ect leading to increases in vascular event rates beyond that of the absence of 
prevention alone [27]. This observed rebound eff ect has been att ributed to the 
inhibition of endothelium nitric oxide synthase (eNOS) mediated pathways by 
statins [27]. Withdrawal of statins is supposed to impair the eNOS mediated 
tension regulation, which in turn may lead to short term increased stress on 
the vessel wall and risk of SAH. It has also been suggested that eNOS has both 
haemodynamic and structural roles [178]. Experimental data from eNOS knockout 
mice models demonstrated that luminal remodelling is impaired in the absence 
of eNOS, suggesting that nitric oxide (NO) derived from eNOS, in addition to 
its role as a vasodilatator, may have a role in controlling vessel wall architecture 
[179]. In order to investigate this association, we conducted a population-based 
case-control study within the PHARMO database (chapter 3.1). During the study 
period 1004 incident cases of SAH were identifi ed. Current use of statins did not 
signifi cantly decrease the risk of SAH (OR=0.77, 95%CI: 0.55-1.07), although there 
was a tendency. The odds ratio for recent withdrawal compared to none users was 
1.62 (95%CI: 0.96-2.73). Compared to current use, recent withdrawal was associated 
with an increased risk of SAH (OR=2.34, 95%CI: 1.35-4.05). Interaction analysis 
showed that the eff ect of statin withdrawal was highest in patients who had also 
recently stopped anti-hypertensive drugs (OR=6.77, 95%CI: 2.10-21.8). The excess 
risk of SAH in this combination of withdrawal of statins during uncontrolled blood 
pressure is probably due to impaired NO bioavailability when it is most needed. 
The endothelium usually copes with increases in blood pressure by releasing NO 
to the smooth muscles around the vessel which subsequently relax [180].
 Another drug class of interest for us were the antithrombotic agents (chapter 
3.2). Use of platelet aggregation inhibitors and oral anticoagulants (vitamin 
K antagonists) have both been associated with increased risk of intracranial 
haemorrhage (ICH) [28]. It remains unclear whether and to what extent these 
antithrombotic agents are associated specifi cally with SAH, as this has not 
been separated out [25, 29]. Since these agents are frequently given to prevent 
(recurrent) cardiovascular events, observed associations are liable to confounding 
by indication. We used several approaches to study the association and the impact 
of confounding on these estimates. In our case-control analysis the adjusted odds 
ratio (OR) for the risk of SAH in current use of platelet aggregation inhibitors was 
1.32 (95% CI: 1.02-1.70) and in current use of vitamin K antagonists 1.29 (95% CI: 
0.89-1.87) compared to no use. In the case-crossover analysis, which eff ectively 
deals with confounding factors that remain stable over time within a person, 
platelet aggregation inhibitors were not associated with SAH anymore (OR=1.04, 
95% CI: 0.56-1.94), but the eff ect for vitamin K antagonists became much stronger 
(OR=2.46, 95% CI: 1.04-5.82). To further investigate this change in fi ndings we 
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examined whether an increase in use of these drugs over time (which may bias 
a case-crossover analysis) could explain this change. In the case-time-control 
analysis, which takes this time varying user prevalence into account, the OR for 
platelet aggregation inhibitors changed to 0.50 (95% CI: 0.26-0.98) and for vitamin 
K antagonists to 1.98 (95% CI: 0.82-4.76). To be conservative, we concluded that 
use of platelet aggregation inhibitors was not associated with an increased SAH 
risk; the modest increase observed in the case-control analysis could be explained 
by confounding. Use of vitamin K antagonists seemed to be associated with an 
increased risk of SAH. The increase was most pronounced in the case-crossover 
analysis and therefore cannot be explained by unmeasured confounding. This is 
important from a clinical perspective as it might indicate that patients with an 
unruptured aneurysm should preferentially be treated with platelet aggregation 
inhibitors. It is unlikely that vitamin K antagonists will cause a rupture, but they 
may aggravate minor leaks. 
 Based on fi ndings regarding preponderance in SAH incidence in women 
aft er the fourth decade of life, we hypothesized that a disbalance in sex hormones 
may infl uence SAH risk. Therefore, we investigated the eff ect of oral contraceptive 
pills (OCP) on SAH (chapter 3.3). We observed that OCP use was associated with 
an increased risk of SAH of 1.79 (95% CI: 1.22-2.64) in PHARMO. In IPCI the risk 
was increased as well, but not statistically signifi cant. Subdivision according to 
progestin content showed that levonorgestrel was associated with an 89 percent 
increase in SAH risk (OR=1.89, 95% CI: 1.24-2.87). Desogestrel was associated with 
a 98 percent increase (OR=1.98, 95% CI: 1.11-3.54). In IPCI the association between 
OCP use and aneurysmal SAH was 2.32 (95% CI: 0.89-6.05). The association 
between use of levonorgestrel containing OCP and aneurysmal SAH was 4.28 
(95% CI: 1.65-11.1). We therefore concluded in two diff erent populations that use 
of OCP are associated with an increased risk of SAH and aneurysmal SAH.
Genetic risk loci
A previous genome-wide association study (GWAS) of intracranial aneurysms 
reported that identifi ed three risk loci on chromosomes 8q11.23-q12.1, 9p21.3 and 
2q33.1 with P < 5 × 10-8 [34]. That study had limited power to detect loci imparting 
genotypic relative risk (GRR) < 1.35. To study additional loci of similar or smaller 
eff ect a second GWAS was conducted in a larger cohort. The study comprised 
5,891 cases and 14,181 controls with ~832,000 genotyped and imputed SNPs across 
discovery cohorts. Our study had 89% and 64% average power to detect common 
variants (minor allele frequencies (MAF) ≥ 10%) with GRR of 1.25 and 1.20, 
respectively. We identifi ed three new loci showing strong evidence for association 
with intracranial aneurysms in the combined dataset, including intervals near 
RBBP8 on 18q11.2 (OR = 1.22, P = 1.1 × 10−12), STARD13-KL on 13q13.1 (OR = 1.20, 
P = 2.5 × 10-9) and a gene-rich region on 10q24.32 (OR = 1.29, P = 1.2 × 10-9). We 
also confi rmed prior associations near SOX17 (8q11.23–q12.1; OR = 1.28, P = 1.3 
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× 10−12) and CDKN2A-CDKN2B (9p21.3; OR = 1.31, P = 1.5 × 10-22). Several of the 
putative risk genes play a role in cell-cycle progression, potentially aff ecting the 
proliferation and senescence of progenitor-cell populations that are responsible 
for vascular formation and repair.
Predicting outcome aft er aneurysmal subarachnoid haemorrhage
Early prediction of short term outcome in terms of case-fatality may support clinical 
decision making in patients admitt ed with an aneurysmal SAH and may provide 
realistic and evidence based expectations to patients and relatives. Predictions 
may also be used to classify patients according to prognosis, which may be 
useful to compare outcome between diff erent patient series, to study treatment 
results over time, or to stratify patients for randomised clinical trials (RCT). We 
developed prediction models for outcome aft er aneurysmal SAH. Data were 
collected prospectively by the International Subarachnoid Aneurysm Trial (ISAT). 
The fi rst model focussed on the binary outcome case-fatality within 60 days. The 
study population comprised of 2,128 patients who had been randomised to either 
endovascular coiling or neurosurgical clipping (chapter 4.1). In this population 153 
patients (7.2%) died within 60 days. World Federation of Neurosurgical Societies 
(WFNS) grade was the most important predictor of case-fatality, followed by age, 
lumen size of the aneurysm and Fisher grade. The model discriminated reasonably 
between those who died within 60 days and those who survived (c statistic = 0.73), 
with minor optimism according to bootstrap re-sampling (optimism corrected c 
statistic = 0.70). The probability of dying within 60 days is calculated according to 
the logistic formula: 1/(1 + exp-LP). The linear predictor (LP) describes the model 
represented by an intercept and regression coeffi  cients for the predictor values.
 The second model focussed on the ordinal outcome ‘modifi ed Rankin Scale’ 
(mRS) at two month assessment (chapter 4.2). This is an ordered scale for measuring 
disability and runs from 0 (no symptoms at all) to 6 (dead). The prediction model 
included WFNS grade, age, sex, lumen size of the aneurysm, Fisher grade, 
vasospasm on angiography, and treatment modality. The model discriminated 
moderately between those with poor and good mRS scores (c statistic = 0.65), with 
minor optimism according to bootstrap re-sampling (optimism corrected c statistic 
= 0.64). 
Methodological considerations
Population based SAH research 
LMR
For our study on the incidence of SAH we use the nationwide hospital registry 
(Landelĳ ke Medische Registratie, LMR). The LMR database contains discharge 
diagnoses and admission details of nearly all Dutch general and university 
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hospitals. Discharge diagnoses and procedures are coded by trained personnel 
in the hospital. In this database, we identifi ed all patients with the diagnose 
code for SAH during a certain period. Our main concern in this procedure was 
misclassifi cation of outcome. A small validation study of discharge diagnoses in 
our own hospital showed that 10 percent of the cases were false positive. Another 
major concern was patients who died before reaching medical care; they were not 
included in the incidence estimate. Previous studies have estimated the percentage 
of persons dying outside hospitals to be between 11 and 13 percent [41, 42]. 
 The major advantage of the LMR database is its completeness with regard 
to the Dutch hospitals. Registration of discharge diagnoses was obligatory for all 
hospitals. The limitations of the LMR data concern covariates and misclassifi cation. 
Since LMR is a hospital discharge database, covariates can only be assessed in so far 
they have led to a hospital admission. Only an overall disease score can be assigned 
to patients [181-183]. Validation of cases to reduce or quantify misclassifi cation is 
generally not possible in LMR data. It would request de-anonymisation of at least 
the hospitals from which the cases are obtained. Secondly, permission has to be 
obtained to go through patient fi les to verify the diagnoses.
PHARMO 
The pharmacoepidemiological studies in this thesis used data from PHARMO 
Record Linkage System (RLS) [70]. This database, which is representative for the 
Dutch population, includes drug-dispensing records from community pharmacies 
and hospital discharge records of more than two million community dwelling 
inhabitants of 50 demographically defi ned areas in the Netherlands. For all 
residents, the computerized drug-dispensing histories contain data concerning the 
dispensed drug, type of prescriber, dispensing date, dispensed amount, prescribed 
dosing regimens, and the legend duration of use (prescription length). All drugs 
are coded according to the Anatomical Therapeutic Chemical (ATC) Classifi cation 
[76]. The hospital records include detailed information concerning discharge 
diagnosis, procedures, dates of hospital admission and discharge, and discharge 
destination or dying in the hospital before discharge. Diagnoses are classifi ed 
according to the International Classifi cation of Diseases, Ninth Revision, Clinical 
Modifi cation (ICD-9-CM). For the studies in this thesis we used cases of SAH. 
 The advantageous feature of PHARMO is that it links hospital discharge data 
and pharmacy data.
 This database was used to increase the power of the studies on drug and 
outcome associations performed in IPCI. However, a major limitation in PHARMO 
is that is not possible to distinguish between SAH in general and aneursymal SAH 
specifi cally. Another limitation concerns the impracticality of case validation, 
which is similar to that in the LMR database.
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IPCI
For some studies in this thesis, data was obtained from the Integrated Primary Care 
Information (IPCI) database which contains anonimized medical records of around 
one million general practitioner’s patients. The database is representative for the 
Dutch population regarding age and sex. In the Netherlands, general practitioners 
act as gatekeepers for secondary care [184]. Consequently, their records can be 
considered to hold most relevant medical information about a patient. No paper 
records are being kept by general practitioners participating in the project except 
for specialist lett ers which can be requested for the case validation process. Given 
the rarity of the disease under study, using large databases is mandatory to collect 
enough cases for meaningful results. Since data in the IPCI database was collected 
prospectively and irrespective of the research question, selection bias plays no role. 
 The major advantage of the IPCI database compared with the others is the 
possibility of case validation. We used the specialist lett ers to manually validate 
aneurysmal SAH cases obtained from the IPCI database. The limitation of this 
database was the relatively small size. Also the fact that SAH is a pre-eminently 
specialist diagnosis makes the search for these patients in a GP database an indirect 
one. 
Pharmacoepidemiology in subarachnoid haemorrhage; bias and 
confounding
Studying associations between drugs and SAH in electronic medical record 
databases is challenging due to a variety of potential biases and mechanisms of 
confounding. In all observational studies, various types of bias, e.g. selection bias, 
protopathic bias, information bias and confounding by indication, may infl uence 
the study fi ndings. We will discuss these forms of bias in the context of the 
studies that were performed. The primary study design that was adopted in the 
pharmacoepidemiological studies in this thesis was the case-control study. Case-
control studies are more effi  cient in studying dose, duration and exposure responses 
than cohort studies, whereas their validity is the same in case of information from 
electronic medical records, since data collection is always independent from the 
study question and recall bias, which plagues fi eld case-control studies, is not an 
issue.
 The potential for selection bias was minimal in our studies as all data were 
obtained from prospectively collected medical records that are maintained for 
patient care or health care policy purposes on a population level. 
 Protopathic bias occurs when a drug is used to treat prodromic symptoms of 
the study outcome. In statistical analysis it may appear as if the drug is positively 
associated to the outcome [185]. One could erroneously conclude that the drug 
causes the outcome. In our statin withdrawal study described in chapter 3.1 
protopathic bias was observed for pain medication. We found increased odds 
ratios for NSAIDs, coxibs, and anti-migraine medication, as the prodromes of SAH 
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are most likely headache and neck pain due to a ‘warning leak’. Our suspicion of 
protopathic bias was supported by the sub analyses in patients using these agents 
for more than 30 days; in these patients the association could not be found which 
argues against a causal relation.
 Information bias can occur as result of misclassifi cation of either exposure or 
outcome. To minimize the potential eff ect of information bias by misclassifi cation 
of the outcome a three-step validation process was undertaken where feasible. 
Validation was performed in IPCI cases. First, all potential cases were identifi ed 
by means of a broad search of coded diagnoses and free text narratives in the 
electronic medical record of all patients. Second, electronic medical records of all 
potential cases were manually reviewed and validated by a medical doctor. Finally, 
specialist lett ers concerning all probable and defi nite cases were reviewed by a 
medical doctor and a neurologist. During the validation process reviewers were 
blinded to drug exposure. Due to this extensive validation process, false positives 
are highly unlikely in the IPCI cases. However, false negatives remain a concern in 
incidence studies as they cannot be ruled out. In case control studies, this is less of 
a concern due to study design. 
 As elaborated above, misclassifi cation of outcome was a limitation in the 
studies performed in the PHARMO and LMR databases, since the opportunities 
for extensive validation were limited due to the nature of the databases. The 
performed search was basically a search for International Classifi cation of Diseases, 
Ninth Revision (ICD-9) code 430; subarachnoid haemorrhage.
 Misclassifi cation of exposure was a concern in the pharmocoepidemiological 
studies in this thesis since we used prescription and dispensing data and had no 
information on actual use of the medication. Misclassifi cation is likely to be non-
diff erential between cases and controls and would lead to underestimation of 
the association between drug use and outcome. To deal with misclassifi cation of 
exposure due to irregular intake, we performed various sensitivity analyses in our 
studies by varying the exposure window. In our study on statin use, sensitivity 
analyses on diff erent risk windows of withdrawal showed that the association 
measure is highest when withdrawal is closest to the index date, i.e. persons who 
stopped more recently. In the OCP study the association was stronger for the 
longer exposure windows. In the case-control design of the antithrombotics study 
the tendency was similar as in the OCP study. In the case-crossover and case-time-
control designs of the antithrombotics study, sensitivity analyses did not show 
changes in point estimates.
One highly important issue that was encountered in our epidemiological studies 
was confounding by indication. Confounding by indication refers to an extraneous 
determinant of the outcome parameter that is present if a perceived high risk 
or poor prognosis is an indication for medical intervention. In our studies the 
indication is a confounder because it correlates with the drug prescription and is a 
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risk indicator for the disease under study [186]. Confounding by indication is likely 
in several of the associations studied, since the choice of cardiovascular drug is 
oft en associated with the condition of the patient, which in itself can be a risk factor 
for SAH. Confounding by indication was addressed in the design and analysis 
phases of the studies. In the study on statin withdrawal we compared patients 
who stopped using statins with current users to reduce the impact of indication 
of use as a confounder. There is a strong potential for confounding by indication, 
since statins are regularly used in patients with increased cardiovascular risk, 
which is also a risk factor for SAH [1]. In the antithrombotics study confounding 
by indication was taken into account by applying a case-crossover design [78]. 
The indication for platelet aggregation inhibitors is mostly secondary prevention 
of cardiovascular and cerebrovascular disease. These share many risk factors 
with SAH and may therefore cause confounding by indication. But in a case-
crossover study the patient acts as its own control, so potential, both measured 
and unmeasured, confounders that are stable over time cancel out. Confounding 
by indication was less pronounced in the OCP studies since birth control is not 
associated itself with SAH, apart from transient diff erences in sexual activity, 
which may be a risk factor [36].
 Due to the use of electronic medical records, we could consider many risk 
factors in IPCI. In PHARMO, we could only adjust for drug proxies of confounding 
factors and therefore residual confounding cannot be excluded. We could also either 
adjust main analyses for potential confounder or match on patient characteristics. 
However, secondary use of medical record data renders our study vulnerable to 
potential confounders that are not covered in the database. In the case-control 
designs in PHARMO we could not adjust for lifestyle factors such as smoking, 
alcohol abuse, obesity, and actual blood pressure. Nonetheless, in the case of the 
antithrombotic study we could address this residual confounding by applying a 
case-crossover design.
Modelling SAH outcome
ISAT
Data for our modelling studies were obtained from the International Subarachnoid 
Aneurysm Trial (ISAT) [152]. Thus, the modelling studies used data from one large 
trial on a selected population of patients in equipoise regarding treatment with 
either endovascular coiling or neurosurgical clipping, which limits generalizability. 
Nonetheless, according to a recently published paper, the ISAT population 
proved to be quite similar to the population admitt ed with an aneurysmal SAH 
to neurosurgical units in the United Kingdom [156]. Although in the ISAT, a 
lower proportion of poor grade patients were enrolled. Therefore, results from 
these modelling studies should be validated externally, i.e. in independent data 
on survival and outcome in aneurysmal SAH patients. Unless external validation 
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proves these models valid, they should not be directly used in clinical sett ing. Let 
alone be applied for treatment limiting decisions.
Ordinal outcomes
Outcome status in the medical domain is oft en measured as an ordered categorical 
scale. So far, it is not evident what method should be applied to model these 
ordinal outcomes satisfactory. The abundance of proposed models makes it hard 
to decide where to start and what to aim at. From a theoretical perspective, it is 
nearly impossible to make a start. From a pragmatic point of view, starting with 
a straightforward extension of the well known logistic regression model (LRM) 
is a reasonable fi rst step. The extended version of LRM is the proportional odds 
(PO) model. The advantage of the PO model is its parsimony in dealing with an 
ordered outcome. The price we pay is the assumption of proportionality of the 
odds. This assumption is equivalent to saying that any cut-point on the outcome 
scale would lead to the same (binary) logistic regression coeffi  cient [153]. However, 
the dependence of our PO model on the assumption of proportionality should 
not be overstressed. The potential inaccuracy caused by mild violation of the PO 
assumption is in all likelihood not more severe than would be the case in arbitrary 
dichotomisation of an ordinal outcome. Especially since dichotomisation involves 
loss of information [174]. Probably one would prefer a “wrong, but useful” model, 
despite possibly violating some underlying model assumptions [175]. Moreover, 
the PO model predicts the probability of being in each outcome level for each 
individual patient. This makes the model useful for all patients, regardless of 
severity.
Suggestions for future research
Pharmacoepidemiology
Studies in this thesis show the potential and pitfalls of use of electronic 
medical records for assessing associations between drug use and subarachnoid 
haemorrhage. A need exists to systematically investigate these associations, since 
they represent potential avoidable risk factors for SAH. New methodologies are 
warranted and in development to evaluate and quantify the benefi t-risk profi les of 
several drugs [187]. Use of electronic medical record databases seem key in these 
assessments since they refl ect reality rather than artifi cial trial circumstances and 
allow for longer follow up. Added to that, not all drugs currently under interest 
in SAH research have been recently investigated in a trial sett ing, let alone for the 
specifi c purpose of examining cerebrovascular risk profi les. In case of severe and 
rare clinical outcomes, such as SAH, a single electronic medical record database 
may not provide suffi  cient subjects and heterogeneity in exposure to conduct 
sound pharmocoepidemiologic research in the full range of drugs of interest. For 
General discussion | 101
this reason we combined results from diff erent databases to study the association 
between oral contraceptive pill use and SAH. Combination of results is a fi rst step 
towards eventual aggregation of data from diff erent sources. Currently, such an 
approach is challenging due to diff erences in languages and medical terminology 
applied. Added to that, researchers should cope with substantial diff erences in 
quality and type of data. This strategy however may provide enough statistical 
power to study rare diseases and rare drug exposures. Methodologies for 
analyzing aggregated data from diff erent sources have been proposed in the fi eld 
of intracranial aneurysms [188]. Similar methodologies in other fi elds are now 
being investigated in multidisciplinary research consortia [189-191]. They should 
be optimalized and made available for other diseases and fi elds of research in the 
future. 
Modelling
There seems to be reasonable unanimity on modelling binary outcomes. Recently, 
a very broad yet concise and therefore practically useful book on development, 
validation and updating clinical prediction models has been published [153]. 
For medical researchers, the information in the book probably suffi  ces to 
develop prediction models with binary clinical outcomes. The case for ordered 
categorical outcomes is not so straightforward. Modelling ordinal outcomes 
is fairly complicated from a statistical point of view, but very important from 
a medical one. Oft en, outcome status in the medical domain is measured as an 
ordered categorical scale. Many models have been proposed and an abundance 
of programs in several statistical packages is available [176, 177]. However, for the 
medical researcher without a background in statistics or mathematics it is nearly 
impossible to weigh all possibilities and perform sound research. Therefore, future 
research and sound advice from supportive research disciplines on this important 
issue would be of great help.
 Another direction of future research in prediction modelling in neurovascular 
disease is how to deal with missing data. Many suggestions have been made on 
how to impute data [192, 193]. But methods for imputation and modelling in one 
go will have to be developed and promoted in the fi eld of medical research [194, 
195].
 
Unruptured intracranial aneurysms
Since 85 percent of SAH originates from an intracranial aneurysm it might 
prove worthwhile to try and target unruptured aneurysms before they rupture. 
Population prevalence of unruptured aneurysms has been estimated at 2 percent 
[13] and the estimated yearly rupture rate of unruptured aneurysm is around 
1 percent [196]. Future research should focus on identifying risk factors for 
harbouring, development, or rupture of an unruptured intracranial aneurysm. 
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 Genome wide association studies (GWAS) proved to be able to detect genetic 
variances that are associated with intracranial aneurysms [35]. More risk loci are 
to be expected from future GWAS.
 Another fi eld of future research should be the development of aneurysms 
[197, 198]. High risk populations will have to be defi ned and decision modelling 
will have to be applied to investigate whether screening proves benefi cial and cost 
eff ective. 
Individualized risk assessment
The ultimate goal of research in the fi eld of SAH and unruptured intracranial 
aneurysms will be to develop individualised risk prediction models. A reasonable 
amount of knowledge on rupture risk has been gathered in a recent review of 
reviews [22]. Added to information on patient and aneurysm characteristics, 
imaging biomarkers such as with electrocardiographically gated CT angiography 
(4D CTA) for visualizing pulsation of intracranial aneurysms and morphodynamic 
analysis of cerebral aneurysm pulsation might prove of great value for this goal 
[158, 159]. 
 Within the @neurIST consortium considerable eff orts have been put in the 
development of computer-interpretable guideline services and individualised 
risk prediction models [188, 199]. Future research in medical practice should use 
the benefi ts from technologies in which digital data enables predictable outcomes 
through quantitative models that integrate physical processes across spatial scales 
down to the molecular level. It should focus on personalized, predictive, integrative 
and evidence-based approaches to medicine. These will use computational tools to 
link individual patient data with virtual population databases via the knowledge 
of biological processes encoded in mathematical models [200]. 
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6.1 Summary 
Subarachnoid haemorrhage (SAH) is bleeding into the subarachnoid space ‒ the 
area between the arachnoid membrane and the pia mater surrounding the brain. 
SAH originates from arteries localised on the brain’s surface. SAH can be caused 
by traumatic injury of the head or can occur spontaneously. Spontaneous SAH 
is caused by rupture of an intracranial aneurysm in about 85 percent of cases. 
Reliable knowledge about the risks of (aneurysmal) SAH in diff erent populations 
will help in screening and prevention strategies and in predicting the prognosis of 
individual patients. One of the overall aims of the research presented in this thesis 
was to provide evidence for the development of an individualised prediction 
model that would allow predicting behaviour of an unruptured aneurysm and 
outcome of eventual rupture of an aneurysm. This work was performed as part of 
the European @neurIST project.
 The specifi c aim of this thesis was to investigate the incidence, aetiology, and 
outcome of intracranial aneurysms and SAH.
In chapter 2 we report on the incidence, treatment, and case-fatality of (aneurysmal) 
SAH in the Netherlands. Recent data on the Dutch situation were missing, so 
we tried to fi ll the gap by means of a population-based study. We found that the 
Netherlands belong to low incidence countries, as opposed to high incidence 
countries such as Finland and Japan, where the incidence is twice as high as in 
most other countries. The majority of aneurysmal SAH patients was treated by 
means of a neurosurgical clipping procedure. Case-fatality proved to be high: up 
to one-third of SAH patients died within one month aft er onset.
In chapter 3.1 we report on the eff ect of statin withdrawal on SAH risk. Since 
nitric oxide (NO) has been suggested to be involved in SAH related vasospasm, 
and withdrawal of statins is supposed to impair the endothelium NO synthase 
mediated tension regulation, which in turn may lead to short term increased stress 
on the vessel wall and risk of SAH, we hypothesized that statins infl uence the 
risk of SAH during use and shortly aft er withdrawal. In this chapter we showed 
that statins are indeed associated with the risk of SAH. Whereas current use of 
statins may protect against SAH, withdrawal is associated with a clear increase in 
risk, especially if patients have also stopped antihypertensive drugs. The observed 
results support our hypothesis that statins have an eff ect on vascular endothelium 
and are associated with SAH risk. 
Chapter 3.2 was a quest to investigate the association between certain 
antithrombotic drugs ‒ platelet aggregation inhibitors and vitamin K antagonists ‒ 
and SAH. These drugs have been associated with an increased risk of intracranial 
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haemorrhage. Whether use of these antithrombotic drugs is associated with an 
increased risk of SAH previously remained unclear, especially since confounding 
by indication might play a role. We applied three diff erent study designs to 
approach the problem of elucidating the association, while taking potential 
confounding by indication into account. We found that use of platelet aggregation 
inhibitors was not associated with an increased SAH risk, whereas use of vitamin 
K antagonists was associated with an increased risk of SAH. This implicates that 
vitamin K antagonists should be prescribed cautiously in patients with known 
unruptured aneurysms. 
In chapter 3.3 we describe a study on the association between use of oral 
contraceptive pills (OCP) and (aneurysmal) SAH risk. The fact that the age-specifi c 
incidence rate of SAH is higher in postmenopausal women than in men suggests 
an infl uence of sex hormones. Based on epidemiological fi ndings, evidence that 
endothelium-dependent arterial vasodilatation increases signifi cantly during 
the ovulatory phase of the menstrual cycle, when oestrogen levels are highest in 
naturally cycling young women, and studies showing that some progestins may 
antagonize the benefi cial vascular eff ects of oestrogen in postmenopausal women, 
it is logical that the type of progestin used in OCP may determine how diff erent 
OCPs aff ect the arterial vasculature in young women. Although the association has 
been under debate for a long time, previous studies remained inconclusive on the 
subject. In this study we observed that use of OCP seems to be associated with an 
increased risk of (aneurysmal) SAH.
In chapter 3.4 a study on genetics of intracranial aneurysms is described. This 
study has been performed by a large multinational consortium. In this study we 
report on a genome-wide association study with discovery and replication cohorts 
from the United States of America, Europe, and Japan comprising nearly six 
thousand cases and fourteen thousand controls with over eight hundred thousand 
genotyped and imputed single nucleotide polymorphisms across discovery 
cohorts. We identifi ed three new loci showing strong evidence for association with 
intracranial aneurysms. We also confi rmed two previously found associations. 
Several of the putative risk genes play a role in cell-cycle progression, potentially 
aff ecting the proliferation and senescence of progenitor-cell populations that are 
responsible for vascular formation and repair.
In chapter 4.1 we present a prediction model of the outcome in terms of case-fatality 
within sixty days from the onset of aneurysmal SAH. Our aim was to develop this 
model based on clinical features and neuro-imaging, regularly readily available 
on admission to a neurological or neurosurgical unit. Early prediction of short 
term outcome in terms of case-fatality may support clinical decision making and 
may provide realistic and evidence based expectations to patients and relatives. 
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Predictions may also be used to classify patients according to prognostic risk, 
which may be useful to compare outcome between diff erent patient series, to study 
treatment results over time, or to stratify patients for randomised clinical trials. In 
the internally validated fi nal model age, lumen size of the aneurysm, Fisher grade, 
and World Federation of Neurosurgical Societies (WFNS) grade were included 
as predictors. The model fi tt ed the data in which it was developed well and the 
c statistic showed that the model discriminates reasonably between patients who 
die within sixty days from onset of the aneurysmal SAH and those who survive 
this period.
The study presented in chapter 4.2 is the sequel of this prediction research. A 
frequently used outcome measurement in stroke research is the modifi ed Rankin 
Scale. This is an ordered scale for measuring motor function and runs from zero (no 
symptoms at all) to six (dead). Outcomes at ordinal scales are oft en dichotomized. 
However, there are several objections against collapsing an ordinal outcome scale 
into a binary one. The most important objection being that from a clinical point of 
view dichotomisation may lead to less useful models. For example, for a patient 
with a minor stroke a model predicting survival versus mortality is of limited 
value since the risk is low, while a prediction of complete recovery versus some 
remaining symptoms may be very useful. For a patient with a severe stroke, this 
will be the other way around. An alternative for dichotomisation is application of 
a statistical approach that uses the full ordinal outcome scale. This leads to effi  cient 
use of the data and clinically relevant predictions. Our aim was to develop an 
ordinal prognostic model to predict clinical outcome at two months in patients 
with aneurysmal SAH. For the sake of interpretability and clinical usefulness, 
we chose to accept a minor violation of the proportional odds assumption in 
the proportional odds model we applied. Age and WFNS grade were the most 
important predictors in the internally validated multivariable proportional 
odds model. Other statistically signifi cant predictors were sex, lumen size of the 
aneurysm, Fisher grade, vasospasm, and treatment modality. However, the model 
poorly fi tt ed the data in which it was developed and the c statistic of the fi nal 
model showed moderate discrimination between patients in diff erent outcome 
categories.
In chapter 5 the results and conclusions are summarized and interpreted. The 
scientifi c consequences of our fi ndings are discussed. Further, we explore some 
methodological issues and give suggestions for further research.
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6.2 Samenvatt ing
Een subarachnoïdale bloeding (SAB) is een bloeding in de subarachnoïdale ruimte 
tussen het spinnewebvlies (arachnoidea mater) en het zachte hersenvlies (pia mater) 
die om de hersenen liggen. Een SAB ontspringt aan de bloedvaten die rondom de 
hersenen liggen in de subarachnoïdale ruimte. Een SAB kan veroorzaakt worden 
door een traumatische verwonding van het hoofd of kan spontaan optreden. Een 
spontane SAB wordt in ongeveer 85 procent van de gevallen veroorzaakt door 
ruptuur van een intracranieel aneurysma. Betrouwbare kennis over de risico’s op 
een (aneurysmatische) SAB in verschillende populaties helpt bĳ  beslissingen over 
screening en preventie en in het voorspellen van de prognose van individuele 
patiënten. Een van de overkoepelende doelstellingen van het onderzoek, dat in dit 
proefschrift  wordt beschreven, was het leveren van evidence voor het ontwikkelen 
van een geïndividualiseerd predictiemodel dat het gedrag van een niet-
geruptureerd aneurysma en de uitkomst van een eventuele ruptuur zou kunnen 
voorspellen. Het onderzoek werd uitgevoerd als onderdeel van het Europese@
neurIST project. Het specifi eke doel van dit proefschrift  was het onderzoeken van 
etiologie en uitkomst van intracraniële aneurysma’s en SAB.
In hoofdstuk 2 worden gegevens gerapporteerd betreff ende incidentie en 
behandeling van een SAB en het overlĳ den ten gevolge van een SAB in Nederland. 
Aangezien recente Nederlandse gegevens ontbraken, hebben wĳ  geprobeerd het 
gat te dichten met een populatiegebaseerde studie. We vonden dat Nederland 
behoort tot landen met een lage incidentie, in tegenstelling tot bĳ voorbeeld Finland 
en Japan, waar de incidentie ongeveer twee keer zo hoog is als in andere landen. 
De meerderheid van de SAB-patiënten werd behandeld door het neurochirurgisch 
plaatsen van een clip op het aneurysma. Het aantal patiënten dat overleed ten 
gevolge van of vlak na een SAB was hoog: tot een derde van de SAB-patiënten 
overleed binnen een maand na het optreden van de SAB.
In hoofdstuk 3.1 beschrĳ ven we het eff ect van ontt rekking van statinen op 
het SAB-risico. Aangezien eerder gesuggereerd is dat stikstofmonoxide (NO) 
betrokken is bĳ  SAB-gerelateerde vasospasmen en ontt rekking van statinen 
verondersteld wordt de endotheel-NO-synthasegemedieerde regulatie van de 
vaatwandspanning te verslechteren, was onze hypothese dat statinen het risico op 
SAB beïnvloeden tĳ dens gebruik en kort na ontt rekking. In dit hoofdstuk toonden 
wĳ  aan dat statinen inderdaad geassocieerd zĳ n met het risico op een SAB. Gebruik 
van statinen biedt mogelĳ k bescherming tegen een SAB, maar ontt rekking is 
geassocieerd met een duidelĳ k verhoogd risico, vooral bĳ  patiënten die ook gestopt 
zĳ n met het nemen van bloeddrukverlagende middelen. De gevonden resultaten 
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steunen onze hypothese dat statinen een eff ect hebben op het vasculaire endotheel 
en geassocieerd zĳ n met het risico op een SAB. 
Hoofdstuk 3.2 was een zoektocht naar de associatie tussen bloedverdunners – in 
dit geval plaatjesremmers en vitamine K antagonisten – en SAB. Deze middelen 
zĳ n eerder geassocieerd met intracraniële bloedingen. Of deze bloedverdunners 
een verhoogd SAB-risico met zich meebrengen is tot nog toe onduidelĳ k gebleven, 
vooral doordat confounding by indication een rol zou kunnen spelen. We hebben 
drie verschillende studie-opzett en toegepast om de mogelĳ ke associatie te bepalen 
en tegelĳ kertĳ d rekening te houden met confounding by indication. We vonden 
dat het gebruik van plaatjesremmers niet geassocieerd was met een verhoogd 
SAB-risico, maar het gebruik van vitamine K antagonisten wel. Dit impliceert 
dat er oplett endheid betracht dient te worden bĳ  het voorschrĳ ven van vitamine 
K antagonisten aan patiënten, van wie bekend is dat zĳ  een niet-geruptereerd 
intracranieel aneurysma hebben.
In hoofdstuk 3.3 beschrĳ ven we een studie naar de associatie tussen het gebruik 
van ‘de pil’ (orale anticonceptie) en een (aneurysmatische) SAB. De bevinding 
dat leeft ĳ dsspecifi eke incidentie van SAB hoger is in postmenopausale vrouwen 
suggereert dat geslachtshormonen van invloed zĳ n op het optreden van een 
SAB. Wanneer we ons baseren op epidemiologische bevindingen, bewĳ s dat 
endotheelafh ankelĳ ke arteriële vasodilatatie signifi cant toeneemt tĳ dens de 
ovulatiefase in de menstruatiecyclus, wanneer oestrogeenspiegels het hoogst zĳ n 
in jonge vrouwen met een natuurlĳ ke cyclus en studies die aantonen dat sommige 
progestagenen het gunstige vasculaire eff ect van oestrogenen tegenwerken in 
postmenopausale vrouwen, is het waarschĳ nlĳ k dat het type progestageen in 
de pil bepaalt wat het vasculaire eff ect van de pil is bĳ  jonge vrouwen. Hoewel 
deze associatie al geruime tĳ d onderwerp van discussie is, bleef een defi nitieve 
conclusie op basis van eerdere studies uit. In onze studie zagen we dat pilgebruik 
geassocieerd leek met een verhoogd risico op een (aneurysmatische) SAB.
In hoofdstuk 3.4 wordt een studie beschreven over genetica van intracraniële 
aneurysmata. Deze studie is uitgevoerd door een groot multinationaal consortium. 
In deze studie beschrĳ ven we een genome-wide association study met ontdek- en 
replicatiecohorten uit de Verenigde Staten, Europa en Japan die bĳ na zesduizend 
cases en veertienduizend controles bevatt en waarin meer dan achthonderdduizend 
single nucleotide polymorphisms (SNPs) zĳ n onderzocht. Er zĳ n drie nieuwe loci 
geïdentifi ceerd met krachtig bewĳ s voor associatie met intracraniële aneurysmata. 
Tevens zĳ n twee eerder gevonden associaties bevestigd. Het is vermeldenswaardig 
dat de genen, die vermoedelĳ k door de regio’s van de gevonden SNPs gecodeerd 
worden, een rol spelen in de voortgang van de celcyclus en daardoor mogelĳ k 
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een rol spelen in de proliferatie en veroudering van voorlopercelpopulaties die 
verantwoordelĳ k zĳ n voor vorming en reparatie van vaatstructuren.
In hoofdstuk 4.1 presenteren we een predictiemodel voor de uitkomst van een 
aneurysmatische SAB na zestig dagen in termen van overlĳ den. Ons doel was 
om dit model te ontwikkelen gebaseerd op klinische en neuroradiologische 
kenmerken, die doorgaans beschikbaar zĳ n bĳ  opname op een neurologische of 
neurochirurgische afdeling. Tĳ dige voorspelling van de kortetermĳ nuitkomst in 
termen van overlĳ den zou het maken klinische beslissingen kunnen ondersteunen 
en zou realistische en evidence based verwachtingen voor patiënten en verwanten 
kunnen opleveren. Predicties kunnen ook worden gebruikt om patiënten te 
classifi ceren op basis van hun prognose, wat gebruikt kan worden om uitkomsten 
te vergelĳ ken tussen verschillende patiëntenseries, om behandelingsresultaten 
over de tĳ d te bestuderen of om patiënten te stratifi ceren voor gerandomiseerde 
klinische trials. In het intern gevalideerde uiteindelĳ ke model waren leeft ĳ d, 
groott e van het aneurysma, Fisher gradering en World Federation of Neurosurgical 
Societies (WFNS) gradering opgenomen als voorspellers. Het model paste goed op 
de gegevens waarop het was ontwikkeld en de c-waarde toonde dat het model 
redelĳ k onderscheid kan maken tussen patiënten die binnen zestig dagen na SAB 
overlĳ den en patiënten die deze periode overleven.
De studie die wordt beschreven in hoofdstuk 4.2 is het vervolg op dit predictie-
onderzoek. Een veelvuldig gebruikte uitkomstmaat in beroerte-onderzoek is de 
modifi ed Rankin Scale. Dit is een ordinale schaal om motorische functie te meten 
en loopt van nul (geen symptomen) tot zes (dood). Ordinale uitkomsten worden 
vaak gedichotomiseerd. Echter, er zĳ n bezwaren tegen het samenvoegen van 
ordinale categorieën om een binaire uitkomst te krĳ gen. Het belangrĳ kste bezwaar 
is dat dichotomiseren kan leiden tot een model dat vanuit klinisch oogpunt 
minder bruikbaar is. Het is bĳ voorbeeld niet heel zinvol voor een patiënt met een 
lichte beroerte de kans op overlĳ den te voorspellen, aangezien die heel laag is 
en andere uitkomsten veel relevanter zĳ n voor deze patiënt. Een alternatief voor 
dichotomiseren van de uitkomst is het toepassen van een statistische benadering die 
de volledige ordinale schaal benut. Dat leidt tot effi  ciënt gebruik van de gegevens 
en klinisch relevante modellen. Ons doel was het ontwikkelen van een ordinaal 
predictiemodel om de klinische uitkomst twee maanden na een SAB te voorspellen. 
Omwille van interpreteerbaarheid en klinische bruikbaarheid hebben we een milde 
schending van de aanname van proportionaliteit van de kansen geaccepteerd 
in het model dat we hebben toegepast. Leeft ĳ d en WFNS gradering waren de 
belangrĳ kste voorspellers in het intern gevalideerde multivariabele proportionele-
kans-model. Andere statistisch signifi cante voorspellers waren geslacht, groott e 
van het aneurysma, Fisher gradering, vasospasme en behandelingsmodaliteit. 
Echter, het model paste matig op de gebruikte gegevens. De c-waarde toonde een 
110 | Chapter 6.2
matig vermogen van het model om patiënten met verschillende uitkomsten te 
onderscheiden. 
In hoofdstuk 5 worden de resultaten en conclusies samengevat en geïnterpreteerd 
en worden de wetenschappelĳ ke consequenties van onze bevindingen besproken. 
Voorts wordt in dit hoofdstuk ingegaan op enkele methodologische onderwerpen 
en worden suggesties gedaan voor verder onderzoek.
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